US6765087B1
(en)
*
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
DK0698097T3
(da)
|
1993-04-29 |
2001-10-08 |
Unilever Nv |
Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
|
EP0739981A1
(de)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
|
US20040248201A1
(en)
*
|
1996-06-27 |
2004-12-09 |
Serge Muyldermans |
Recognition molecules interacting specifically with the active site or cleft of a target molecule
|
CA2258518C
(en)
*
|
1996-06-27 |
2011-11-22 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Recognition molecules interacting specifically with the active site or cleft of a target molecule
|
AU735695B2
(en)
*
|
1996-10-10 |
2001-07-12 |
Neose Technologies, Inc. |
Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
|
US20030228310A1
(en)
*
|
1996-12-23 |
2003-12-11 |
Advanced Biotherapy, Inc. |
Treatment of skin diseases
|
BR9907241A
(pt)
*
|
1998-01-26 |
2000-10-17 |
Unilever Nv |
Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
|
CA2327505A1
(en)
*
|
1998-04-28 |
1999-11-04 |
Smithkline Beecham Corporation |
Monoclonal antibodies with reduced immunogenicity
|
CN100434441C
(zh)
|
1999-04-22 |
2008-11-19 |
荷兰联合利华有限公司 |
利用单价抗原-结合蛋白抑制病毒感染
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
TR200200194T2
(tr)
|
1999-07-27 |
2002-05-21 |
Unilever N.V. |
Beyazlatıcı deterjan terkipleri
|
EP1212100B1
(de)
*
|
1999-09-16 |
2005-04-06 |
Unilever Plc |
Abgabesystem für ein mittel gegen schuppen
|
US6479280B1
(en)
|
1999-09-24 |
2002-11-12 |
Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw |
Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
|
EP1088892A1
(de)
*
|
1999-09-24 |
2001-04-04 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Rekombinante Phagen fähig zur eintritt in gastzellen durch verbindung mit kunstlichem rezeptor
|
EP1242460B1
(de)
|
1999-11-29 |
2006-10-18 |
Unilever Plc |
Immobilisierung von proteinen mit hilfe eines polypeptidsegments
|
EP1118669A3
(de)
*
|
1999-12-17 |
2001-08-29 |
Unilever Plc |
Herstellung von Camelid-Antikörpern in Pflanzen
|
ATE428733T1
(de)
|
2000-03-14 |
2009-05-15 |
Unilever Nv |
Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
|
US6696620B2
(en)
*
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
CA2380443C
(en)
|
2000-05-26 |
2013-03-12 |
Ginette Dubuc |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
US7943129B2
(en)
|
2000-05-26 |
2011-05-17 |
National Research Council Of Canada |
Single-domain brain-targeting antibody fragments derived from llama antibodies
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
CA2429544C
(en)
*
|
2000-11-17 |
2010-10-19 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
US20060064782A1
(en)
*
|
2000-12-18 |
2006-03-23 |
Conopco, Inc. |
Production of antibodies
|
AU2002235761A1
(en)
|
2000-12-19 |
2002-07-01 |
Unilever Plc |
Stabilization of antibodies or fragments thereof
|
ATE519783T1
(de)
*
|
2000-12-22 |
2011-08-15 |
Grad Carole Legal Representative Of Kaplan Howard |
ßPHAGE DISPLAYß BIBLIOTHEKE VON MENSCHLICHEN VH FRAGMENTEN
|
EP1363663B1
(de)
|
2001-01-12 |
2011-03-02 |
Novartis Vaccines and Diagnostics, Inc. |
Nukleinsäure mukosale immunisierung
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20050069538A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Gregorio Aversa |
Therapeutic binding molecules
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
US6861056B2
(en)
*
|
2001-06-05 |
2005-03-01 |
Advanced Biotherapy, Inc. |
Compositions and methods for treating hyperimmune response in the eye
|
US20040062768A1
(en)
*
|
2001-06-05 |
2004-04-01 |
Advanced Biotherapy, Inc. |
Compositions and methods for treating hyperimmune response in the eye
|
US20040086508A1
(en)
*
|
2001-06-05 |
2004-05-06 |
Advanced Biotherapy, Inc. |
Treatment of organ transplant rejection
|
US20050152902A1
(en)
*
|
2001-06-05 |
2005-07-14 |
Advanced Biotherapy, Inc. |
Treatment of diabetic retinopathy
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
US20050037358A1
(en)
*
|
2001-12-21 |
2005-02-17 |
Serge Muyldermans |
Method for cloning of variable domain sequences
|
CA2471645A1
(en)
*
|
2002-01-03 |
2003-07-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Immunoconjugates useful for treatment of tumours
|
WO2003057728A1
(en)
|
2002-01-10 |
2003-07-17 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
A novel splice variant of myd88 and uses thereof
|
AU2002333502A1
(en)
*
|
2002-02-10 |
2003-09-04 |
Apoxis Sa |
Fusion constructs containing active sections of tnf ligands
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
JP2006512895A
(ja)
*
|
2002-06-28 |
2006-04-20 |
ドマンティス リミテッド |
リガンド
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
ATE491725T1
(de)
|
2002-07-15 |
2011-01-15 |
Univ Texas |
Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
|
AU2003251238A1
(en)
|
2002-08-07 |
2004-02-25 |
Umc Utrecht Holding B.V. |
Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
GB0219720D0
(en)
*
|
2002-08-23 |
2002-10-02 |
Univ Aberdeen |
Polypeptide
|
US20040052790A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Advanced Biotherapy, Inc. |
Treatment of schizophrenia
|
WO2010081856A1
(en)
|
2009-01-14 |
2010-07-22 |
Ablynx Nv |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
EP1900753B1
(de)
*
|
2002-11-08 |
2017-08-09 |
Ablynx N.V. |
Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
|
EP2267032A3
(de)
|
2002-11-08 |
2011-11-09 |
Ablynx N.V. |
Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
US20060228355A1
(en)
|
2003-11-07 |
2006-10-12 |
Toon Laeremans |
Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
EP1437764A1
(de)
*
|
2003-01-10 |
2004-07-14 |
S.O.I. Tec Silicon on Insulator Technologies S.A. |
Anpassungsfähiges Substrat für Heteroepitaxie, heteroepitaktische Struktur und Verfahren zur Herstellung eines anpassungsfähigen Substrates
|
CA2512545C
(en)
|
2003-01-10 |
2015-06-30 |
Karen Silence |
Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
|
KR20110094361A
(ko)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
PL1639011T3
(pl)
|
2003-06-30 |
2009-05-29 |
Domantis Ltd |
Pegilowane przeciwciała jednodomenowe (dAb)
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
EP3722309A1
(de)
|
2003-07-28 |
2020-10-14 |
Genentech, Inc. |
Verringerung des protein-a-auslaugens während einer affinitätschromatografie
|
WO2005014795A2
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
WO2005081687A2
(en)
*
|
2003-09-30 |
2005-09-09 |
Centocor, Inc. |
Human hinge core mimetibodies, compositions, methods and uses
|
CA2542886A1
(en)
|
2003-11-05 |
2005-05-19 |
Neelima M. Bhat |
Enhanced b cell cytotoxicity of cdim binding antibody
|
AU2004299457B2
(en)
*
|
2003-12-12 |
2011-03-24 |
Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
WO2005105984A2
(en)
*
|
2004-04-12 |
2005-11-10 |
The Trustees Of The University Of Pennsylvania |
Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
|
JP2008501337A
(ja)
*
|
2004-06-04 |
2008-01-24 |
ジェネンコー・インターナショナル・インク |
抗体重鎖を用いたスクリーニング法
|
US20050276807A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of acne
|
US20050276806A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of autism
|
GB2416768A
(en)
*
|
2004-07-22 |
2006-02-08 |
Univ Erasmus |
Heavy chain immunoglobulin complexes
|
KR101151957B1
(ko)
|
2004-07-22 |
2012-06-01 |
로저 킹돈 크레이그 |
결합 분자
|
US20060177445A1
(en)
*
|
2004-08-16 |
2006-08-10 |
Boris Skurkovich |
Treatment of inflammatory skin diseases
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
KR20070084069A
(ko)
|
2004-10-08 |
2007-08-24 |
도만티스 리미티드 |
Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
|
WO2006044263A2
(en)
*
|
2004-10-12 |
2006-04-27 |
Advanced Biotherapy, Inc. |
Treatment of herpes
|
EP1814917A2
(de)
*
|
2004-10-13 |
2007-08-08 |
Ablynx N.V. |
Anti-amyloid-beta-antikörper aus kameliden und diese enthaltende polypeptide für die behandlung und diagnose degenerativer nervenerkrankungen wie etwa morbus alzheimer
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
EP1836500B1
(de)
|
2005-01-14 |
2010-07-07 |
Ablynx N.V. |
Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
|
JP2008528010A
(ja)
*
|
2005-01-31 |
2008-07-31 |
アブリンクス ナームローゼ フェンノートシャップ |
重鎖抗体の可変ドメイン配列を作出する方法
|
CN101495498B
(zh)
|
2005-02-07 |
2013-09-18 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
EP1855694B1
(de)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense-zusammensetzung zur behandlung von muskelatrophie
|
EP1863849B1
(de)
|
2005-03-11 |
2011-04-27 |
Syngenta Limited |
Bekämpfung von schädlichen nagetieren
|
CA2606018A1
(en)
*
|
2005-04-28 |
2006-11-02 |
Ventana Medical Systems, Inc. |
Nanoparticle conjugates
|
US20060246523A1
(en)
*
|
2005-04-28 |
2006-11-02 |
Christopher Bieniarz |
Antibody conjugates
|
EP2949668B1
(de)
|
2005-05-18 |
2019-08-14 |
Ablynx N.V. |
Verbesserte nanokörper-tm gegen tumornekrosefaktor alpha
|
CA2608873C
(en)
|
2005-05-20 |
2017-04-25 |
Ablynx Nv |
Single domain vhh antibodies against von willebrand factor
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
SI2298815T1
(sl)
*
|
2005-07-25 |
2015-08-31 |
Emergent Product Development Seattle, Llc |
Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
|
EP3190125A1
(de)
|
2005-08-31 |
2017-07-12 |
Merck Sharp & Dohme Corp. |
Mittels engineering hergestellte anti-il-23r-antikörper
|
ES2333260T3
(es)
|
2005-09-01 |
2010-02-18 |
Schering Corporation |
Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
|
CA2623659A1
(en)
*
|
2005-09-27 |
2007-04-05 |
National Research Council Of Canada |
Targeted delivery of compounds using multimerization technology
|
JP5389442B2
(ja)
|
2005-09-29 |
2014-01-15 |
メディミューン,エルエルシー |
膜Ig特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用
|
US7526409B2
(en)
*
|
2005-10-07 |
2009-04-28 |
Oracle International Corporation |
Automatic performance statistical comparison between two periods
|
GB0521139D0
(en)
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
CA2626604A1
(en)
|
2005-10-21 |
2007-04-26 |
Genenews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
GB0522460D0
(en)
*
|
2005-11-03 |
2005-12-14 |
Prendergast Patrick T |
Composition and method for the treatment of avian influenza
|
ES2804129T3
(es)
|
2005-11-23 |
2021-02-03 |
Ventana Med Syst Inc |
Conjugado anticuerpo-enzima
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
EP1976991A1
(de)
*
|
2006-01-24 |
2008-10-08 |
Domantis Limited |
Fusionsproteine mit natürlichen verbindungen
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
*
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
US7504106B2
(en)
*
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
US20100226920A1
(en)
*
|
2006-03-27 |
2010-09-09 |
Ablynx N.V. |
Medical delivery device for therapeutic proteins based on single domain antibodies
|
WO2008054514A2
(en)
*
|
2006-04-21 |
2008-05-08 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and the uses thereof
|
CN101437945A
(zh)
|
2006-05-02 |
2009-05-20 |
阿克托杰尼斯有限公司 |
肥胖相关肽的微生物肠内递送
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
EP2037961B1
(de)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Verfahren zur behandlung von autoimmunerkrankungen anhand von monoklonalen antikörpern mit verminderter toxizität
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
WO2008008360A1
(en)
|
2006-07-13 |
2008-01-17 |
Wyeth |
Production of glycoproteins
|
EP2064243A2
(de)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistische lichtspezifische menschliche monoklonale antikörper
|
PL2698166T3
(pl)
|
2006-10-10 |
2016-03-31 |
Regenesance B V |
Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
EP2442107B1
(de)
|
2006-11-01 |
2014-03-12 |
Ventana Medical Systems, Inc. |
Haptene, Haptenkonjugate, Zusammensetzungen daraus und Verfahren für ihre Herstellung und Verwendung
|
CA2672201A1
(en)
|
2006-11-07 |
2008-05-15 |
Vib Vzw |
Use of myb gene to diagnose and treat t-cell acute lumphoblastic leukemia
|
EP3156415A1
(de)
|
2006-11-22 |
2017-04-19 |
Bristol-Myers Squibb Company |
Gezielte therapeutik auf grundlage manipulierter proteine für tyrosinkinaserezeptoren, einschliesslich igf-ir
|
US20080267949A1
(en)
*
|
2006-12-05 |
2008-10-30 |
Ablynx N.V. |
Peptides capable of binding to serum proteins
|
WO2008076321A1
(en)
|
2006-12-14 |
2008-06-26 |
Schering Corporation |
Engineered anti-tslp antibody
|
EP2514767A1
(de)
|
2006-12-19 |
2012-10-24 |
Ablynx N.V. |
Gegen Metalloproteinase der ADAM-Familie gerichtete Aminosäuren und Polypeptide damit zur Behandlung von Erkrankungen und Störungen im Zusammenhang mit ADAM
|
WO2008074839A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
US20110118185A9
(en)
*
|
2007-02-21 |
2011-05-19 |
Ablynx N.V. |
Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
|
SG178804A1
(en)
|
2007-02-23 |
2012-03-29 |
Schering Corp |
Engineered anti-il-23p19 antibodies
|
EP2059534B1
(de)
|
2007-02-23 |
2012-04-25 |
Schering Corporation |
Gentechnisch hergestellte anti-il-23p19-antikörper
|
JP5337055B2
(ja)
|
2007-02-28 |
2013-11-06 |
メルク・シャープ・アンド・ドーム・コーポレーション |
免疫性障害の処置のための組合せ治療
|
NZ579251A
(en)
|
2007-02-28 |
2012-06-29 |
Schering Corp |
Engineered anti-il-23r antibodies
|
EP2115126B1
(de)
*
|
2007-03-02 |
2015-04-08 |
Wyeth LLC |
Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
|
EP2308514B1
(de)
|
2007-03-23 |
2013-06-05 |
to-BBB Holding B.V. |
Konjugate zum Arzneimitteltransport über die Blut-Hirn-Schranke
|
TW200902708A
(en)
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
ES2540807T3
(es)
|
2007-05-04 |
2015-07-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
|
NZ599278A
(en)
|
2007-05-14 |
2013-12-20 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
AU2008262489B2
(en)
*
|
2007-05-23 |
2013-11-28 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
KR101661357B1
(ko)
|
2007-06-01 |
2016-09-29 |
오픈 모노클로날 테크놀로지, 인코포레이티드 |
내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
|
US20090017460A1
(en)
*
|
2007-06-15 |
2009-01-15 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and uses thereof
|
JP5240870B2
(ja)
|
2007-07-03 |
2013-07-17 |
アブリンクス エン.ヴェー. |
改善した免疫グロブリン配列を提供する方法
|
EP2487190A3
(de)
|
2007-07-13 |
2012-11-14 |
Bac Ip B.V. |
Antigen-bindende Einzeldomänen-Proteine, die Säugetier-IgG binden
|
US20100291593A1
(en)
|
2007-07-13 |
2010-11-18 |
Powell William C |
Method of identifying diagnostic reagents
|
ES2657055T3
(es)
|
2007-08-09 |
2018-03-01 |
Wyeth Llc |
Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
|
ES2667729T3
(es)
|
2007-09-26 |
2018-05-14 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
CN101918579A
(zh)
|
2007-10-22 |
2010-12-15 |
先灵公司 |
完全人抗-vegf抗体和使用方法
|
JP5514399B2
(ja)
*
|
2007-11-02 |
2014-06-04 |
国立大学法人 岡山大学 |
無機硫黄化合物加水分解酵素の製造方法
|
PL2567709T3
(pl)
|
2007-11-02 |
2018-06-29 |
Novartis Ag |
Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
|
CA2703519C
(en)
|
2007-11-09 |
2017-04-18 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
JP2011504740A
(ja)
|
2007-11-27 |
2011-02-17 |
アブリンクス エン.ヴェー. |
ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
WO2009086215A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Wyeth |
Pathway analysis of cell culture phenotypes and uses thereof
|
WO2009099961A2
(en)
|
2008-01-31 |
2009-08-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
DE112009000507T5
(de)
|
2008-03-05 |
2011-02-10 |
Ablynx Nv |
Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
|
CA2720013C
(en)
|
2008-04-03 |
2016-02-16 |
Bart De Strooper |
Single domain antibodies capable of modulating bace activity
|
US9908943B2
(en)
|
2008-04-03 |
2018-03-06 |
Vib Vzw |
Single domain antibodies capable of modulating BACE activity
|
GB0809069D0
(en)
|
2008-05-19 |
2008-06-25 |
Univ Leuven Kath |
Gene signatures
|
EP2260058A2
(de)
|
2008-04-07 |
2010-12-15 |
Ablynx N.V. |
Variable einzeldomänen gegen notch-signalwege
|
WO2009126944A1
(en)
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
CA2721202A1
(en)
|
2008-04-17 |
2009-10-22 |
Hilde Adi Pierrette Revets |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
ES2620285T3
(es)
|
2008-05-02 |
2017-06-28 |
Novartis Ag |
Moléculas de unión con base en fibronectina mejorada y usos de las mismas
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
CA2720728C
(en)
|
2008-06-05 |
2018-04-03 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
GB2461546B
(en)
*
|
2008-07-02 |
2010-07-07 |
Argen X Bv |
Antigen binding polypeptides
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
DK2700651T3
(da)
|
2008-07-18 |
2019-07-22 |
Bristol Myers Squibb Co |
Monovalente sammensætninger til cd28-binding og fremgangsmåder til anvendelse heraf
|
EP2313436B1
(de)
|
2008-07-22 |
2014-11-26 |
Ablynx N.V. |
Gegen multitarget-scavenger-rezeptoren und polypeptide gerichtete aminosäuresequenzen
|
SG10201405377XA
(en)
|
2008-08-05 |
2014-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
WO2010033913A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Icb International, Inc. |
Antibodies, analogs and uses thereof
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
MX2011004558A
(es)
|
2008-10-29 |
2011-06-01 |
Wyeth Llc |
Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
|
MX345226B
(es)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
CN102257003B
(zh)
|
2008-12-19 |
2017-04-05 |
埃博灵克斯股份有限公司 |
用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
|
MX2011006549A
(es)
|
2008-12-19 |
2011-07-20 |
Schering Corp |
Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
|
US20100189919A1
(en)
*
|
2009-01-27 |
2010-07-29 |
Xerox Corporation |
Imaging System And Process Using Monoclonal Antibodies
|
WO2010091182A2
(en)
|
2009-02-04 |
2010-08-12 |
Molecular Innovations |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
|
US10005830B2
(en)
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
EP2230515B1
(de)
|
2009-03-16 |
2014-12-17 |
Agilent Technologies, Inc. |
Passivierung von Oberflächen nach Ligandenkupplung
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
JP6159528B2
(ja)
|
2009-03-24 |
2017-07-05 |
ワイス・エルエルシー |
高濃縮のタンパク質治療薬を生成するための膜蒸発
|
KR20120057563A
(ko)
|
2009-03-31 |
2012-06-05 |
노파르티스 아게 |
Il-12 수용체 베타l 서부유닛에 대해 특이적인 치료용 항체를 사용하는 조성물 및 방법
|
JP5647222B2
(ja)
|
2009-04-10 |
2014-12-24 |
アブリンクス エン.ヴェー. |
Il−6r関連疾患及び障害の治療のためのil−6rに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
|
HUE035240T2
(hu)
|
2009-04-27 |
2018-05-02 |
Novartis Ag |
Készítmények és eljárások az izomerõ növelésére
|
ES2864956T3
(es)
|
2009-04-30 |
2021-10-14 |
Ablynx Nv |
Procedimiento para la producción de anticuerpos de dominio
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
US8945567B2
(en)
|
2009-06-05 |
2015-02-03 |
Ablynx N.V. |
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
|
WO2011000054A1
(en)
|
2009-07-03 |
2011-01-06 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
ES2804450T3
(es)
|
2009-07-10 |
2021-02-08 |
Ablynx Nv |
Método para la producción de dominios variables
|
SG177763A1
(en)
|
2009-07-28 |
2012-03-29 |
Hoffmann La Roche |
Non-invasive in vivo optical imaging method
|
EP3199551A3
(de)
|
2009-07-31 |
2017-10-18 |
E. R. Squibb & Sons, L.L.C. |
Vollständig menschliche antikörper gegen btla
|
DK2464657T3
(en)
|
2009-08-10 |
2015-06-29 |
Morphosys Ag |
New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
|
US9884117B2
(en)
|
2009-09-03 |
2018-02-06 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
ES2788869T3
(es)
|
2009-09-03 |
2020-10-23 |
Merck Sharp & Dohme |
Anticuerpos anti-GITR
|
ES2567030T3
(es)
|
2009-09-03 |
2016-04-19 |
Cancer Research Technology Limited |
Inhibidores de CLEC14A
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
UY32920A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moleculas de unión biespecíficas para la terapia anti-angiogénesis
|
UY32917A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moléculas de unión a dll-4
|
US20110117113A1
(en)
|
2009-10-09 |
2011-05-19 |
Gerald Beste |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
WO2011045079A1
(en)
|
2009-10-15 |
2011-04-21 |
Intercell Ag |
Hepatitis b virus specific human antibodies
|
EP2491056B1
(de)
|
2009-10-22 |
2021-09-15 |
Universiteit Twente |
Vhh zur anwendung bei gewebereperatur, organregeneration, organaustausch und gewebekonstruktion
|
CN110054692A
(zh)
|
2009-10-23 |
2019-07-26 |
米伦纽姆医药公司 |
抗gcc抗体分子及其相关组合物和方法
|
EP3434769B1
(de)
|
2009-10-30 |
2020-11-25 |
Novartis AG |
Unterseitig bindende universelle fibronectin-typ-iii-domänenbibliotheken
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
CA2779384C
(en)
|
2009-11-04 |
2018-02-27 |
Schering Corporation |
Engineered anti-tslp antibody
|
EP2496944A2
(de)
|
2009-11-05 |
2012-09-12 |
Novartis AG |
Prädiktive biomarker für die progression von fibrose
|
EP2507262A1
(de)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
|
EP2954779B1
(de)
|
2009-12-10 |
2019-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mäuse zur produktion von schwerkettigen antikörpern
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
WO2011075786A1
(en)
|
2009-12-23 |
2011-06-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
CN102781959A
(zh)
|
2010-02-05 |
2012-11-14 |
埃博灵克斯股份有限公司 |
能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
|
CN102770767A
(zh)
|
2010-02-10 |
2012-11-07 |
诺瓦提斯公司 |
用于肌肉生长的方法和组合物
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
EP2533814A2
(de)
|
2010-02-11 |
2012-12-19 |
Ablynx N.V. |
Freisetzung von veränderlichen mmunoglobulindomänen und konstrukte daraus
|
PL2533761T3
(pl)
|
2010-02-11 |
2019-09-30 |
Ablynx N.V. |
Sposoby i kompozycje do wytwarzania aerozoli
|
DK2539355T3
(da)
|
2010-02-26 |
2017-01-02 |
Ventana Med Syst Inc |
IN-SITU-hybridisering med polytag-prober
|
JP5826194B2
(ja)
|
2010-03-03 |
2015-12-02 |
アブリンクス ナームローゼ フェンノートシャップ |
二パラトープ性a−ベータ結合ポリペプチド
|
US20130041349A1
(en)
|
2010-03-26 |
2013-02-14 |
Westfaelische Wilhelms-Universitaet Muenster |
Substitute therapy for glucocorticoids
|
US8937164B2
(en)
|
2010-03-26 |
2015-01-20 |
Ablynx N.V. |
Biological materials related to CXCR7
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
CN104961827A
(zh)
|
2010-04-06 |
2015-10-07 |
阿格罗塞文公司 |
农用化学品的特异性输送
|
GB201105584D0
(en)
|
2011-04-01 |
2011-05-18 |
Imp Innovations Ltd |
Cancer methods
|
CA2936532A1
(en)
|
2010-04-20 |
2011-10-27 |
Ventana Medical Systems, Inc. |
Two-color chromogenic in situ hybridization
|
EP2563380B1
(de)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten der cysteinyl-trna-synthetase
|
AU2011248614B2
(en)
|
2010-04-27 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
EP2563383B1
(de)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
ES2552954T3
(es)
|
2010-04-30 |
2015-12-03 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
ES2623805T3
(es)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
|
WO2011139986A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
CN103140233B
(zh)
|
2010-05-03 |
2017-04-05 |
Atyr 医药公司 |
与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
JP6008844B2
(ja)
|
2010-05-04 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
p38MULTI−tRNA合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CA2805267C
(en)
|
2010-05-04 |
2019-07-30 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of fibrosis
|
US8877188B2
(en)
|
2010-05-04 |
2014-11-04 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of non-dermal fibrosis
|
ES2659406T3
(es)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
EP2567234B1
(de)
|
2010-05-07 |
2018-09-19 |
F.Hoffmann-La Roche Ag |
Diagnoseverfahren zum Nachweis von Zellen ex vivo
|
AU2011252990B2
(en)
|
2010-05-14 |
2017-04-20 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
NZ603570A
(en)
|
2010-05-20 |
2014-12-24 |
Ablynx Nv |
Biological materials related to her3
|
EP2575856B1
(de)
|
2010-05-27 |
2017-08-16 |
aTyr Pharma, Inc. |
Therapeutische, diagnostische und antikörperhaltige zusammensetzungen in zusammenhang mit proteinfragmenten von glutaminyl-trna-synthetasen
|
USRE49339E1
(en)
|
2010-06-22 |
2022-12-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the C3D fragment of complement component 3
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
US20130109019A1
(en)
|
2010-07-02 |
2013-05-02 |
Adrian E. Murillo |
Hapten conjugates for target detection
|
CA2805548A1
(en)
|
2010-07-02 |
2012-01-05 |
Vib Vzw |
The role of fragile x mental retardation gene and protein in cancer metastasis
|
WO2012021247A2
(en)
|
2010-07-12 |
2012-02-16 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
GB201014715D0
(en)
|
2010-09-06 |
2010-10-20 |
Vib Vzw |
Nanobodies stabilizing functional conformational states of GPCRS
|
WO2012007880A2
(en)
|
2010-07-16 |
2012-01-19 |
Ablynx Nv |
Modified single domain antigen binding molecules and uses thereof
|
GB201012845D0
(en)
|
2010-07-30 |
2010-09-15 |
Vib Vzw |
Inhibition of dicer function for treatment of cancer
|
KR102434557B1
(ko)
|
2010-08-02 |
2022-08-23 |
리제너론 파아마슈티컬스, 인크. |
Vl 도메인을 포함하는 결합 단백질을 생성하는 마우스
|
WO2012024185A1
(en)
|
2010-08-16 |
2012-02-23 |
Ventana Medical Systems, Inc. |
Substrates for chromogenic detection and methods of use in detection assays and kits
|
JP2013535981A
(ja)
|
2010-08-20 |
2013-09-19 |
ワイス・エルエルシー |
成長因子不含適合細胞の細胞培養
|
CN103080134B
(zh)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
EP2609119B1
(de)
|
2010-08-26 |
2017-10-18 |
Agrosavfe N.V. |
Chitinpolysaccharidantigen-bindende proteine
|
EP2609116A1
(de)
|
2010-08-26 |
2013-07-03 |
Agrosavfe N.V. |
An insekten bindende antikörper
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
EP2621953B1
(de)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biologische stoffe im zusammenhang mit c-met
|
EP2625203A1
(de)
|
2010-10-05 |
2013-08-14 |
Novartis AG |
Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
|
EP2632946B1
(de)
|
2010-10-29 |
2017-12-06 |
Ablynx N.V. |
Verfahren zur herstellung von variablen immunglobulin-einzeldomänen
|
GB201018602D0
(en)
|
2010-11-04 |
2010-12-22 |
Vib Vzw |
MMP8 inactivating antigen binding proteins
|
MX368394B
(es)
|
2010-11-05 |
2019-10-01 |
Eisai Inc |
Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
|
TWI619811B
(zh)
|
2010-11-08 |
2018-04-01 |
諾華公司 |
趨化細胞素受體結合多肽
|
EP2656079A2
(de)
|
2010-12-20 |
2013-10-30 |
Universiteit Gent |
Kristallstruktur eines flt3-ligand-rezeptorkomplexes
|
WO2012089814A1
(en)
|
2010-12-30 |
2012-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigen binding formats for use in therapeutic treatments or diagnostic assays
|
CA3007179C
(en)
|
2010-12-30 |
2021-06-08 |
Ventana Medical Systems, Inc. |
Enhanced deposition of chromogens utilizing pyrimidine analogs
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
EP2670779B1
(de)
|
2011-02-01 |
2017-08-02 |
Bac Ip B.V. |
Gegen epitope in der ch1-domäne menschlicher igg-antikörper gerichtetes antigenbindendes protein
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
EP2683413A1
(de)
|
2011-03-07 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
In-vivo-auswahl therapeutisch aktiver antikörper
|
JP6100704B2
(ja)
|
2011-03-07 |
2017-03-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療用抗体についてのインビボ試験の手段および方法
|
AU2012228424B2
(en)
|
2011-03-14 |
2015-05-07 |
Ventana Medical Systems, Inc. |
A method of analyzing chromosomal translocations and a system therefore
|
EP2686016B1
(de)
|
2011-03-14 |
2019-05-01 |
Cellmid Limited |
Antikörper zur erkennung der n-domäne von midkin
|
DK2691415T3
(en)
|
2011-03-28 |
2018-10-29 |
Ablynx Nv |
PROCEDURE FOR PREPARING SOLID FORMULATIONS CONTAINING VARIABLE SINGLE DOMAINS OF IMMUNOGLOBULIN
|
EP2691418A1
(de)
|
2011-03-28 |
2014-02-05 |
Ablynx N.V. |
Bispezifische gegen cxcr4 gerichtete variable immglobulineinzeldomänen
|
AP2013007046A0
(en)
|
2011-03-30 |
2013-08-31 |
Boehringer Ingelheim Int |
Anticoagulant antidotes
|
JP6130350B2
(ja)
|
2011-03-30 |
2017-05-17 |
アブリンクス エン.ヴェー. |
TNFαに対する単一ドメイン抗体で免疫障害を処置する方法
|
KR102289394B1
(ko)
|
2011-03-31 |
2021-08-13 |
머크 샤프 앤드 돔 코포레이션 |
인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
|
US20130078247A1
(en)
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
US9534039B2
(en)
|
2011-05-09 |
2017-01-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
CN103732625A
(zh)
|
2011-05-27 |
2014-04-16 |
埃博灵克斯股份有限公司 |
使用rankl结合肽抑制骨质吸收
|
US9580480B2
(en)
|
2011-05-31 |
2017-02-28 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
CA2838246C
(en)
|
2011-06-13 |
2018-07-10 |
Csl Limited |
Antibodies against g-csfr and uses thereof
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
PT2723764T
(pt)
|
2011-06-21 |
2018-03-09 |
Univ Leland Stanford Junior |
Domínios de ligação dirigidos contra complexos gpcr:proteína g e suas utilizações derivadas
|
HUE047238T2
(hu)
|
2011-06-23 |
2020-04-28 |
Ablynx Nv |
Szérumalbuminhoz kötõdõ fehérjék
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン.ヴェー. |
IgEに対する免疫グロブリン単一可変ドメイン
|
SI2726099T1
(sl)
|
2011-07-01 |
2018-11-30 |
Novartis Ag |
Postopek za zdravljenje metaboličnih motenj
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
JP2014526886A
(ja)
|
2011-07-15 |
2014-10-09 |
モルフォシス・アー・ゲー |
マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体
|
KR102143506B1
(ko)
|
2011-08-17 |
2020-08-12 |
글락소 그룹 리미티드 |
변형된 단백질 및 펩티드
|
WO2013033073A1
(en)
|
2011-08-31 |
2013-03-07 |
Ventana Medical Systems, Inc. |
Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
EP2753644A1
(de)
|
2011-09-09 |
2014-07-16 |
Universiteit Utrecht Holding B.V. |
Breit neutralisierende vhh gegen hiv-1
|
JP5813880B2
(ja)
|
2011-09-19 |
2015-11-17 |
カイマブ・リミテッド |
ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
|
US20140235492A1
(en)
|
2011-09-20 |
2014-08-21 |
Institut National De La Sante Et De La Recherche Medicate (Inserm) |
Methods for preparing single domain antibody microarrays
|
WO2013041722A1
(en)
|
2011-09-23 |
2013-03-28 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
JP6219287B2
(ja)
|
2011-09-30 |
2017-10-25 |
アブリンクス エン.ヴェー. |
c−Metに関連する生物学的物質
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
CN104080471B
(zh)
|
2011-10-14 |
2018-08-10 |
诺华股份有限公司 |
用于Wnt途径相关疾病的抗体和方法
|
WO2013059206A2
(en)
|
2011-10-17 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii)
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
US9265817B2
(en)
|
2011-10-28 |
2016-02-23 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
WO2013068571A1
(en)
|
2011-11-11 |
2013-05-16 |
Ucb Pharma S.A. |
Albumin binding antibodies and binding fragments thereof
|
WO2013079606A1
(en)
|
2011-12-01 |
2013-06-06 |
Ventana Medical Systems, Inc. |
Automated dual stain of mirna and protein targets
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
US20150147274A1
(en)
|
2011-12-02 |
2015-05-28 |
Cancer Research Technology Limited |
Antibodies against hgf - receptor and uses
|
JP6243345B2
(ja)
|
2011-12-05 |
2017-12-06 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)に対する抗体
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
CN106831985A
(zh)
|
2011-12-21 |
2017-06-13 |
诺华股份有限公司 |
用于抗体靶定p因子的组合物和方法
|
US10112987B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
|
US10112988B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
|
WO2013108126A2
(en)
|
2012-01-16 |
2013-07-25 |
University Of Oslo |
Methyltransferases and uses thereof
|
AU2013209492B2
(en)
|
2012-01-20 |
2018-02-08 |
Genzyme Corporation |
Anti-CXCR3 antibodies
|
WO2013113696A1
(en)
|
2012-01-30 |
2013-08-08 |
Vib Vzw |
Means and method for diagnosis and treatment of alzheimer's disease
|
WO2013121042A1
(en)
|
2012-02-16 |
2013-08-22 |
Vib Vzw |
PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
|
CN108610421B
(zh)
|
2012-02-27 |
2022-08-19 |
阿布林克斯有限公司 |
Cx3cr1结合多肽
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
DK2831587T3
(en)
|
2012-03-27 |
2018-07-23 |
Ventana Med Syst Inc |
Signaling conjugates and methods of use
|
EP2831111B1
(de)
|
2012-03-30 |
2019-03-20 |
Boehringer Ingelheim International GmbH |
Ang2 bindende moleküle
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
CA2874309C
(en)
|
2012-05-24 |
2021-06-15 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
EP2687595B1
(de)
|
2012-07-19 |
2018-05-30 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Verfahren zur Reinigung eines transgenen Faktor VII
|
EP2877211A4
(de)
|
2012-07-25 |
2016-02-10 |
Salk Inst For Biological Studi |
Regelung der interaktion zwischen tam-liganden und lipidmembranen mit exponiertem phosphatidylserin
|
EP4063391A1
(de)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
US9605074B2
(en)
|
2012-08-30 |
2017-03-28 |
The General Hospital Corporation |
Multifunctional nanobodies for treating cancer
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
KR20210063443A
(ko)
|
2012-10-09 |
2021-06-01 |
바이오젠 엠에이 인코포레이티드 |
탈수초성 질환의 치료를 위한 복합 요법 및 용도
|
KR102286389B1
(ko)
|
2012-11-20 |
2021-08-05 |
노파르티스 아게 |
폴리펩티드를 고 수율로 발현하는 최적화 발현 카세트
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
CN104968678B
(zh)
|
2012-12-05 |
2018-12-11 |
诺华股份有限公司 |
靶向epo的抗体的组合物和方法
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
SG11201504676VA
(en)
|
2012-12-14 |
2015-07-30 |
Omt Inc |
Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
|
MX2015007931A
(es)
|
2012-12-18 |
2015-10-05 |
Novartis Ag |
Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
BR112015014621A2
(pt)
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
Anticorpos anti-h7cr
|
CN112858672A
(zh)
|
2013-01-30 |
2021-05-28 |
弗拉芒区生物技术研究所 |
用于筛选和药物发现目的的新型嵌合多肽
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
EP2953973B1
(de)
|
2013-02-05 |
2019-07-10 |
VIB vzw |
Muskarinische acetylcholinrezeptorbinder und verwendungen davon
|
CN104995211B
(zh)
|
2013-02-07 |
2019-09-13 |
Csl有限公司 |
Il-11r结合蛋白及其应用
|
PL2953969T3
(pl)
|
2013-02-08 |
2020-02-28 |
Novartis Ag |
Przeciwciała anty-il-17a i ich zastosowanie w leczeniu zaburzeń autoimmunologicznych i zapalnych
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
MX2015010350A
(es)
|
2013-02-26 |
2015-10-29 |
Roche Glycart Ag |
Moleculas de union a antigeno biespecificas que activan la celula t.
|
DK2962100T3
(da)
|
2013-02-28 |
2021-11-01 |
Caprion Proteomics Inc |
Tuberkulosebiomarkører og anvendelser deraf
|
US10778913B2
(en)
|
2013-03-12 |
2020-09-15 |
Ventana Medical Systems, Inc. |
Digitally enhanced microscopy for multiplexed histology
|
AU2014248515B2
(en)
|
2013-03-13 |
2019-03-07 |
Prothena Biosciences Limited |
Tau immunotherapy
|
EP2970479B1
(de)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antikörper gegen notch 3
|
EP4079760A3
(de)
|
2013-03-15 |
2023-01-25 |
Sanofi Pasteur Inc. |
Antikörper gegen clostridium-difficile-toxine und verfahren zur verwendung davon
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA2906259C
(en)
|
2013-03-15 |
2022-12-06 |
Vib Vzw |
Anti-mmr single variable domains for prognosis and monitoring of cardiovascular diseases
|
CN105518018B
(zh)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
修饰的t淋巴细胞
|
EP2976362B1
(de)
|
2013-03-19 |
2019-10-23 |
Beijing Shenogen Pharma Group Ltd. |
Antikörper und verfahren zur behandlung von östrogenrezeptor-assoziierten erkrankungen
|
JP6388917B2
(ja)
|
2013-04-29 |
2018-09-12 |
アグロサーフエ・エン・フエー |
ポリペプチドからなる農薬組成物
|
EP2994163B1
(de)
|
2013-05-09 |
2019-08-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
WO2014190356A2
(en)
|
2013-05-24 |
2014-11-27 |
Amplimmune, Inc. |
Anti-b7-h5 antibodies and their uses
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
WO2014207173A1
(en)
|
2013-06-27 |
2014-12-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
|
US20160176943A1
(en)
|
2013-07-05 |
2016-06-23 |
Inserm (Insititut National De La Sante Et De La Recherche Medicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
WO2015004633A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize islet-amyloid polypeptide (iapp)
|
WO2015004632A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize iapp
|
ES2650917T3
(es)
|
2013-08-07 |
2018-01-23 |
Alexion Pharmaceuticals, Inc. |
Proteínas biomarcadoras del síndrome urémico hemolítico atípico (SUHA)
|
TW201536318A
(zh)
|
2013-08-14 |
2015-10-01 |
Novartis Ag |
治療偶發性包涵體肌炎之方法
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
DK3074038T3
(en)
|
2013-11-28 |
2019-03-11 |
Csl Ltd |
METHOD OF TREATING DIABETIC NEPHROPATHY
|
EP2883883A1
(de)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
|
KR20160096194A
(ko)
|
2013-12-18 |
2016-08-12 |
씨에스엘 리미티드 |
상처 치료 방법
|
EP3083964B1
(de)
|
2013-12-19 |
2022-01-26 |
Novartis AG |
Menschliche chimäre mesothelin-antigenrezeptoren und verwendungen davon
|
EP3087101A4
(de)
|
2013-12-20 |
2017-12-06 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
EP3083685A2
(de)
|
2013-12-20 |
2016-10-26 |
Intervet International B.V. |
Hundeantikörper mit modifizierten ch2-ch3-sequenzen
|
WO2015100409A2
(en)
|
2013-12-26 |
2015-07-02 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
AU2015217846B2
(en)
|
2014-01-30 |
2019-10-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Opioid receptor binding agents and uses thereof
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
KR102356951B1
(ko)
|
2014-02-11 |
2022-01-27 |
비스테라, 인크. |
뎅기열 바이러스에 대한 항체 분자 및 그의 용도
|
US10675352B2
(en)
|
2014-02-14 |
2020-06-09 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
EP3811970A1
(de)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
KR102601491B1
(ko)
|
2014-03-21 |
2023-11-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
SG11201607015VA
(en)
|
2014-03-21 |
2016-09-29 |
Regeneron Pharma |
V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
|
CA2944402A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
IL296691B2
(en)
|
2014-04-25 |
2023-11-01 |
2Seventy Bio Inc |
MND promoter chimeric antigen receptors
|
PL3134095T3
(pl)
|
2014-04-25 |
2020-10-19 |
Bluebird Bio, Inc. |
Ulepszone sposoby produkcji komórek do adoptywnych terapii komórkowych
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
SG10201805288QA
(en)
|
2014-05-16 |
2018-07-30 |
Ablynx Nv |
Improved immunoglobulin variable domains
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
SG11201610170SA
(en)
|
2014-06-06 |
2017-01-27 |
Bluebird Bio Inc |
Improved t cell compositions
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
EP3160990A2
(de)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Zusammensetzungen und verfahren für proteine mit langer wirkung
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用cd33嵌合抗原受體治療癌症
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
EP3194976B1
(de)
|
2014-07-22 |
2020-04-01 |
Vib Vzw |
Verfahren zur auswahl von agenten, die proteinkomplexe stabilisieren
|
US20170226216A1
(en)
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
US20180036442A1
(en)
|
2014-07-29 |
2018-02-08 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
|
US9855348B2
(en)
|
2014-07-29 |
2018-01-02 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
|
EP3660042B1
(de)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
T-zellen mit teilmengenoptimierten chimären antigenrezeptoren
|
JP6649358B2
(ja)
|
2014-08-07 |
2020-02-19 |
ノバルティス アーゲー |
アンジオポエチン様4抗体および使用法
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
CN112410363A
(zh)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
AP2017009765A0
(en)
|
2014-08-19 |
2017-02-28 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
US11344620B2
(en)
|
2014-09-13 |
2022-05-31 |
Novartis Ag |
Combination therapies
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
WO2016054555A2
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
JP6876608B2
(ja)
|
2014-10-03 |
2021-05-26 |
ナノティックス,エルエルシー |
可溶性生体分子の生物学的活性を阻害するための組成物及び方法
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US10561805B2
(en)
|
2014-10-10 |
2020-02-18 |
Ablynx N.V. |
Methods of treating RSV infections
|
CN106999420B
(zh)
|
2014-10-10 |
2021-08-10 |
埃博灵克斯股份有限公司 |
用于呼吸系统疾病的气溶胶疗法的吸入装置
|
AU2015333687B2
(en)
|
2014-10-14 |
2021-03-18 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to PD-L1 and uses thereof
|
US10584175B2
(en)
|
2014-10-23 |
2020-03-10 |
La Trobe University |
FN14-binding proteins and uses thereof
|
EP3215624B1
(de)
|
2014-11-05 |
2023-11-29 |
Biotalys NV |
Transgene pflanzen mit einem für die variable domäne eines schwerkettigen antikörpers codierendem polynukleotid
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
KR20170087500A
(ko)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
KR102584938B1
(ko)
|
2014-12-12 |
2023-10-05 |
2세븐티 바이오, 인코포레이티드 |
Bcma 키메릭 항원 수용체
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
EP3233918A1
(de)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Kombinationstherapien
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
US11426468B2
(en)
|
2014-12-19 |
2022-08-30 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
AU2015367224B2
(en)
|
2014-12-19 |
2020-12-10 |
Monash University |
IL-21 antibodies
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体及びその使用
|
US10273300B2
(en)
|
2014-12-29 |
2019-04-30 |
The Trustees Of The University Of Pennsylvania |
Methods of making chimeric antigen receptor-expressing cells
|
US10870699B2
(en)
|
2014-12-30 |
2020-12-22 |
Celgene Corporation |
Anti-CD47 antibodies and uses thereof
|
PL3240801T3
(pl)
|
2014-12-31 |
2021-06-14 |
Checkmate Pharmaceuticals, Inc. |
Skojarzona immunoterapia nowotworów
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
GB201501004D0
(en)
|
2015-01-21 |
2015-03-04 |
Cancer Rec Tech Ltd |
Inhibitors
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
WO2016124558A1
(en)
|
2015-02-03 |
2016-08-11 |
Ventana Medical Systems, Inc. |
Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
|
JP6871866B2
(ja)
|
2015-02-03 |
2021-05-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
抗rho gtpaseコンホーメーションシングルドメイン抗体及びその使用
|
US20180022781A1
(en)
|
2015-02-13 |
2018-01-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
EP3061826A1
(de)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus-replikons
|
FI3265123T3
(fi)
|
2015-03-03 |
2023-01-31 |
|
Vasta-aineita, käyttöjä & menetelmiä
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
EP3274724A1
(de)
|
2015-03-25 |
2018-01-31 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur messung der proteaseaktivität von faktor d des alternativen komplementweges
|
US20180087087A1
(en)
|
2015-03-25 |
2018-03-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
|
BR112017020275A8
(pt)
|
2015-03-31 |
2023-01-31 |
Sorriso Pharmaceuticals Inc |
Polipeptídeos
|
EP3954710A3
(de)
|
2015-04-02 |
2022-07-20 |
Intervet International B.V. |
Antikörper gegen interleukin-4-rezeptor-alpha des hundes
|
CN107646039B
(zh)
|
2015-04-02 |
2022-04-15 |
埃博灵克斯股份有限公司 |
具有有效抗hiv活性的双特异性cxcr4-cd4多肽
|
EP3280795B1
(de)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Kombination von chimärer antigen rezeptor therapie und amino pyrimidin derivaten
|
WO2016166110A1
(en)
|
2015-04-13 |
2016-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
|
US9778265B2
(en)
|
2015-04-16 |
2017-10-03 |
The United States Of America, As Represented By The Secretary Of The Navy |
Charged peptide appendage to facilitate oriented protein covalent immobilization
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
WO2016168601A1
(en)
|
2015-04-17 |
2016-10-20 |
Khalid Shah |
Agents, systems and methods for treating cancer
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US10259882B2
(en)
|
2015-05-07 |
2019-04-16 |
Agenus Inc. |
Anti-OX40 antibodies
|
EP3736287A1
(de)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Autoimmunantikörper zur verwendung in der hemmung des krebszellenwachstums
|
AU2016259792B2
(en)
|
2015-05-13 |
2019-07-25 |
Ablynx N.V. |
T cell recruiting polypeptides based on TCR alpha/beta reactivity
|
US11046767B2
(en)
|
2015-05-13 |
2021-06-29 |
Ablynx N.V. |
T cell recruiting polypeptides based on CD3 reactivity
|
KR101997241B1
(ko)
|
2015-05-21 |
2019-07-09 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
WO2016191659A1
(en)
|
2015-05-28 |
2016-12-01 |
Bio-Rad Laboratories, Inc. |
Affinity ligands and methods relating thereto
|
PL3303394T3
(pl)
|
2015-05-29 |
2020-11-16 |
Agenus Inc. |
Przeciwciała anty-ctla-4 i sposoby ich zastosowania
|
AU2016273028B2
(en)
|
2015-06-05 |
2019-02-14 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
|
EP3307777A4
(de)
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Neuartige anti-pd-l1-antikörper
|
EP3314260B1
(de)
|
2015-06-24 |
2021-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur detektion von protein-protein-interaktionen
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
US11298433B2
(en)
|
2015-07-17 |
2022-04-12 |
Vrije Universiteit Brussel |
Radiolabelled antibody fragments for use in treating cancer
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
US20190008983A1
(en)
|
2015-07-31 |
2019-01-10 |
James R. Prudent |
Extracellular drug conjugates targeting cd20
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
US11236159B2
(en)
|
2015-08-03 |
2022-02-01 |
Novartis Ag |
Methods of treating FGF21-associated disorders
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
CN107922479A
(zh)
|
2015-08-07 |
2018-04-17 |
默克专利股份公司 |
用于有效的位点特异性生物缀合的转谷氨酰胺标签
|
MA42626A
(fr)
|
2015-08-11 |
2018-06-20 |
Open Monoclonal Tech Inc |
Nouveaux anticorps anti-pd-1
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
KR20180037294A
(ko)
|
2015-08-31 |
2018-04-11 |
블루버드 바이오, 인코포레이티드. |
항-시알릴 Tn 키메라 항원 수용체
|
BR112018003186A2
(pt)
|
2015-09-01 |
2018-09-25 |
Agenus Inc. |
anticorpos anti-pd-1 e seus métodos de uso
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
CA2996635A1
(en)
|
2015-09-09 |
2017-03-16 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Cd3結合ポリペプチド
|
US11203634B2
(en)
|
2015-10-07 |
2021-12-21 |
Alexion Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
CN105238759B
(zh)
*
|
2015-10-14 |
2019-05-24 |
吉日木图 |
抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
|
EP3374391B1
(de)
|
2015-11-10 |
2024-04-17 |
Visterra, Inc. |
Antikörpermolekülarzneimittelkonjugate die an lipopolysaccharide binden und verwendungen davon
|
NO2768984T3
(de)
|
2015-11-12 |
2018-06-09 |
|
|
US20180327499A1
(en)
|
2015-11-13 |
2018-11-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
JO3739B1
(ar)
|
2015-11-18 |
2021-01-31 |
Merck Sharp & Dohme |
روابط ctla4
|
TW202216787A
(zh)
|
2015-11-18 |
2022-05-01 |
美商默沙東藥廠 |
Pd1及/或 lag3結合劑
|
WO2017091683A1
(en)
|
2015-11-25 |
2017-06-01 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
MX2018006377A
(es)
|
2015-11-27 |
2018-09-05 |
Ablynx Nv |
Polipeptidos que inhiben cd40l.
|
ES2821099T3
(es)
|
2015-12-04 |
2021-04-23 |
Boehringer Ingelheim Int Gmbh & Co Kg |
Polipéptidos biparatópicos antagonistas de la señalización WNT en células tumorales
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
US10829562B2
(en)
|
2015-12-10 |
2020-11-10 |
Katholieke Universiteit Leuven |
Haemorrhagic disorder due to ventricular assist device
|
BR112018012352A2
(pt)
|
2015-12-16 |
2018-12-11 |
Merck Sharp & Dohme Corp. |
anticorpos anti-lag3 e fragmentos de ligação ao antígeno
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
PD−1に対する抗体分子とC−Met阻害剤との組合せおよびその使用
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
CD32bを標的とする抗体およびその使用方法
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
JP2019500874A
(ja)
|
2015-12-28 |
2019-01-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞の作製方法
|
JP6991979B2
(ja)
|
2016-02-05 |
2022-03-04 |
オリオニス バイオサイエンシズ ビーブイ |
Cd8結合物質
|
AU2017219254B2
(en)
|
2016-02-17 |
2019-12-12 |
Novartis Ag |
TGFbeta 2 antibodies
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
AU2017238172A1
(en)
|
2016-03-21 |
2018-09-13 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
EP3433615A1
(de)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verfahren zur diagnose und behandlung von sonnenpigmentflecken
|
CN108779180B
(zh)
|
2016-03-23 |
2020-10-16 |
迈博斯生物医药(苏州)有限公司 |
新型抗-pd-l1抗体
|
EP3433275A1
(de)
|
2016-03-24 |
2019-01-30 |
Millennium Pharmaceuticals, Inc. |
Verfahren zur behandlung gastrointestinaler immunbedingter negativer ereignisse bei immunonkologischen behandlungen
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
US20170274076A1
(en)
|
2016-03-25 |
2017-09-28 |
Visterra, Inc. |
Formulations of antibody molecules to dengue virus
|
WO2017176762A1
(en)
|
2016-04-06 |
2017-10-12 |
Nanotics, Llc |
Particles comprising subparticles or nucleic acid scaffolds
|
WO2017178554A1
(en)
|
2016-04-13 |
2017-10-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
|
WO2017181098A2
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
WO2017181119A2
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective protein expression
|
WO2017182605A1
(en)
|
2016-04-22 |
2017-10-26 |
Université Libre de Bruxelles |
A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
WO2017182603A1
(en)
|
2016-04-22 |
2017-10-26 |
Université Libre de Bruxelles |
A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
CN109071647B
(zh)
|
2016-04-27 |
2022-11-22 |
诺华股份有限公司 |
抗生长分化因子15的抗体及其用途
|
EP3452507B1
(de)
|
2016-05-02 |
2022-10-19 |
Prothena Biosciences Limited |
Tau-immuntherapie
|
US20190127447A1
(en)
|
2016-05-02 |
2019-05-02 |
Ablynx N.V. |
Treatment of rsv infection
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
PL3458478T3
(pl)
|
2016-05-18 |
2021-06-28 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
|
BR112018073739A2
(pt)
|
2016-05-20 |
2019-02-26 |
Harpoon Therapeutics, Inc. |
proteína de ligação de albumina sérica de domínio único
|
JP7042467B2
(ja)
|
2016-05-20 |
2022-03-28 |
ハープーン セラピューティクス,インク. |
単鎖可変フラグメントcd3結合タンパク質
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
US20190292259A1
(en)
|
2016-05-24 |
2019-09-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
US11534496B2
(en)
|
2016-06-07 |
2022-12-27 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
|
WO2017216724A1
(en)
|
2016-06-15 |
2017-12-21 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
US11197902B2
(en)
|
2016-06-24 |
2021-12-14 |
Ig Biosciences Corporation |
Prebiotic neutraceutical compositions and methods of treatment using the same
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
KR20190039937A
(ko)
|
2016-07-08 |
2019-04-16 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
MX2019000327A
(es)
|
2016-07-13 |
2019-04-11 |
Biogen Ma Inc |
Regímenes de dosificación de antagonistas de lingo-1 y usos para el tratamiento de trastornos desmielinizantes.
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
SG11201900677SA
(en)
|
2016-07-28 |
2019-02-27 |
Novartis Ag |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
CN110072887A
(zh)
|
2016-08-02 |
2019-07-30 |
威特拉公司 |
工程化多肽及其应用
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
EP3512880A1
(de)
|
2016-09-15 |
2019-07-24 |
Ablynx NV |
Gegen makrophagenmigrationshemmenden faktor gerichte variable immunglobulin-einzeldomänen
|
KR20190049866A
(ko)
|
2016-09-20 |
2019-05-09 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 항-pcsk9 항체
|
KR20240035625A
(ko)
|
2016-09-21 |
2024-03-15 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
EP3515948A4
(de)
|
2016-09-23 |
2020-04-08 |
CSL Limited |
Gerinnungsfaktorbindende proteine und verwendungen davon
|
WO2018057955A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
EP3519438A1
(de)
|
2016-09-30 |
2019-08-07 |
VHsquared Limited |
Zusammensetzungen
|
EP3523331A1
(de)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimäre antigenrezeptoren zur behandlung von krebs
|
MA46529A
(fr)
|
2016-10-11 |
2019-08-21 |
Agenus Inc |
Anticorps anti-lag-3 et leurs procédés d'utilisation
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
EP3526250A1
(de)
|
2016-10-12 |
2019-08-21 |
Alexion Pharmaceuticals, Inc. |
Wirksamkeit eines anti-c5-antikörpers bei der prävention einer antikörpervermittelten abstossung bei sensibilisierten empfängern eines nierentransplantats
|
GB2605540B
(en)
|
2016-10-18 |
2022-12-21 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
US11965884B2
(en)
|
2016-10-19 |
2024-04-23 |
Alexion Pharmaceuticals, Inc. |
Method of quantitating unbound C5 in a sample
|
US11828683B2
(en)
|
2016-10-19 |
2023-11-28 |
Alexion Pharmaceuticals, Inc. |
Method of quantitating unbound C5a in a sample
|
SI3529262T1
(sl)
|
2016-10-21 |
2021-12-31 |
Inserm - Institut National De La Sante Et De La Recherche Medicale |
Postopki za spodbujanje odgovora T-celic
|
EP3532845A1
(de)
|
2016-10-27 |
2019-09-04 |
Alexion Pharmaceuticals, Inc. |
Test zur c5b-9-deposition bei komplementassoziierten erkrankungen
|
WO2018081578A1
(en)
|
2016-10-28 |
2018-05-03 |
Astute Medical, Inc. |
Use of antibodies to timp-2 for the improvement of renal function
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
CA3042989A1
(en)
|
2016-11-07 |
2018-05-11 |
Junho Chung |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
DK3541833T3
(da)
|
2016-11-17 |
2024-04-02 |
2Seventy Bio Inc |
TGFß signalkonverter
|
WO2018091720A1
(en)
|
2016-11-21 |
2018-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
MX2019006045A
(es)
|
2016-11-23 |
2019-11-11 |
Harpoon Therapeutics Inc |
Proteinas triespecificas dirigidas a psma y metodos de uso.
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
US10610104B2
(en)
|
2016-12-07 |
2020-04-07 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
JP6992068B2
(ja)
|
2016-12-07 |
2022-02-03 |
アジェナス インコーポレイテッド |
抗ctla-4抗体およびそれらの使用方法
|
JP7237834B2
(ja)
|
2016-12-14 |
2023-03-13 |
ビオラ・セラピューティクス・インコーポレイテッド |
消化管疾病のil-12/il-23阻害薬による治療
|
US20200315540A1
(en)
|
2016-12-14 |
2020-10-08 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
CA3046019A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
CA3045472A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
CA3045931A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
CA3045310A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
TW201834711A
(zh)
|
2016-12-14 |
2018-10-01 |
美商寶珍那提公司 |
以tnf抑制劑治療胃腸道疾病
|
EP3554346B1
(de)
|
2016-12-14 |
2024-01-31 |
Biora Therapeutics, Inc. |
Behandlung von erkrankungen des gastrointestinaltraktes mit einem immunsuppressivum
|
EP4190318A1
(de)
|
2016-12-14 |
2023-06-07 |
Biora Therapeutics, Inc. |
Behandlung einer erkrankung des magen-darm-trakts mit einem jak-hemmer und vorrichtungen
|
EP3360898A1
(de)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
|
JP7360324B2
(ja)
|
2016-12-23 |
2023-10-12 |
ビステラ, インコーポレイテッド |
結合ポリペプチドおよびそれを作製する方法
|
JP7139332B2
(ja)
|
2016-12-23 |
2022-09-20 |
ノバルティス アーゲー |
第xi因子抗体および使用方法
|
MA47215A
(fr)
|
2017-01-09 |
2019-11-13 |
Bioxcel Therapeutics Inc |
Procédés prédictifs et diagnostiques pour le cancer de la prostate
|
CN110431150A
(zh)
|
2017-01-18 |
2019-11-08 |
威特拉公司 |
抗体分子-药物偶联物及其用途
|
AU2018210420A1
(en)
|
2017-01-19 |
2019-08-08 |
Omniab, Inc. |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
MX2019009255A
(es)
|
2017-02-06 |
2019-11-05 |
Orionis Biosciences Nv |
Proteínas quiméricas dirigidas y sus usos.
|
WO2018146594A1
(en)
|
2017-02-08 |
2018-08-16 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
EP3589647A1
(de)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp-inhibitor-zusammensetzungen und verwendungen zur chimären antigenrezeptortherapie
|
BR112019017853A2
(pt)
|
2017-02-28 |
2021-04-27 |
Vib Vzw |
Meios e métodos para liberação oral de proteína
|
EP3589662A4
(de)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
Induzierbares monovalentes antigenbindendes protein
|
US20200064341A1
(en)
|
2017-03-14 |
2020-02-27 |
Nanotag Biotechnologies Gmbh |
Target detection using a monovalent antibody
|
EP3596126A4
(de)
|
2017-03-15 |
2021-03-03 |
Tsinghua University |
Neuartige anti-trkb-antikörper
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
AU2018240117A1
(en)
|
2017-03-24 |
2019-09-19 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for preventing and treating heart disease
|
WO2018183182A1
(en)
|
2017-03-27 |
2018-10-04 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
WO2018183929A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
JP2020515579A
(ja)
|
2017-03-30 |
2020-05-28 |
プロジェニティ, インコーポレイテッド |
消化管疾病の生菌生物学的製剤による治療
|
WO2018183934A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
US11596670B2
(en)
|
2017-03-30 |
2023-03-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
US20200088732A1
(en)
|
2017-04-13 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Mèdicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
WO2018192974A1
(en)
|
2017-04-18 |
2018-10-25 |
Université Libre de Bruxelles |
Biomarkers and targets for proliferative diseases
|
WO2018195283A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
EP3612561A1
(de)
|
2017-04-19 |
2020-02-26 |
Alexion Pharmaceuticals, Inc. |
Wirksamkeit eines anti-c5-antikörpers bei der prävention einer antikörpervermittelten abstossung bei sensibilisierten empfängern eines nierentransplantats
|
CN110506056A
(zh)
|
2017-04-21 |
2019-11-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体和其使用方法
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
PL3618863T3
(pl)
|
2017-05-01 |
2023-11-06 |
Agenus Inc. |
Przeciwciała anty- tigit i sposoby ich zastosowania
|
CA3062238A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
EP3621648A4
(de)
|
2017-05-12 |
2021-01-20 |
Harpoon Therapeutics, Inc. |
Auf trispezifische proteine abzielendes msln und verfahren zur verwendung
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
CN110662760A
(zh)
|
2017-05-12 |
2020-01-07 |
奥古斯塔大学研究所公司 |
人甲胎蛋白特异性t细胞受体及其用途
|
WO2018222587A1
(en)
|
2017-05-30 |
2018-12-06 |
The Regents Of The University Of California |
NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
|
EP3630836A1
(de)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
|
EP3630816B1
(de)
|
2017-05-31 |
2024-03-20 |
Boehringer Ingelheim International GmbH |
Polypeptidantagonisierende wnt-signalisierung in tumorzellen
|
AU2018277343A1
(en)
|
2017-06-02 |
2020-01-02 |
Ablynx N.V. |
Adamts binding immunoglobulins
|
TWI811220B
(zh)
|
2017-06-02 |
2023-08-11 |
比利時商艾伯林克斯公司 |
結合聚集蛋白聚糖之免疫球蛋白
|
KR20200015912A
(ko)
|
2017-06-02 |
2020-02-13 |
메르크 파텐트 게엠베하 |
Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
|
CA3061053A1
(en)
|
2017-06-02 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
JP2020521804A
(ja)
|
2017-06-02 |
2020-07-27 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Mmp13結合免疫グロブリン
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
EP3415010A1
(de)
|
2017-06-13 |
2018-12-19 |
Agrosavfe Nv |
Insektenkontrollierende polypeptide und verfahren
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
EP3642240A1
(de)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antikörpermoleküle gegen cd73 und verwendungen davon
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2019006007A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
|
CN110785433A
(zh)
|
2017-06-28 |
2020-02-11 |
诺华股份有限公司 |
预防和治疗尿失禁的方法
|
JP2020526584A
(ja)
|
2017-06-28 |
2020-08-31 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体−薬物コンジュゲートおよびその使用
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
EP3652209A2
(de)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonistische antikörper zur bindung von humanem cd137 und verwendungen davon
|
IL307197A
(en)
|
2017-07-11 |
2023-11-01 |
Alexion Pharma Inc |
Polypeptides that bind to the C5 component or serum albumin and their fusion proteins
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
KR102625929B1
(ko)
|
2017-07-19 |
2024-01-16 |
브이아이비 브이지더블유 |
혈청 알부민 결합제
|
CA3070095A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
CN116271012A
(zh)
|
2017-07-27 |
2023-06-23 |
瑞颂医药公司 |
高浓度抗c5抗体制剂
|
JP2020529605A
(ja)
|
2017-08-01 |
2020-10-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
濾過およびクロマトグラフィ用ポッドならびにその使用方法
|
US20200306516A1
(en)
|
2017-08-14 |
2020-10-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
CN111133005A
(zh)
|
2017-09-07 |
2020-05-08 |
奥古斯塔大学研究所公司 |
程序性细胞死亡蛋白1抗体
|
CN111655340A
(zh)
|
2017-09-20 |
2020-09-11 |
国家医疗保健研究所 |
用于调节自噬的方法和药物组合物
|
EP3461841B1
(de)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
|
KR20200058540A
(ko)
|
2017-10-02 |
2020-05-27 |
비스테라, 인크. |
Cd138에 대한 항체 분자 및 이의 용도
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
US11713356B2
(en)
|
2017-10-13 |
2023-08-01 |
Ose Immunotherapeutics |
Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
|
EP3694871A4
(de)
|
2017-10-13 |
2021-11-10 |
Harpoon Therapeutics, Inc. |
B-zellreifungs-antigenbindende proteine
|
US11136403B2
(en)
|
2017-10-13 |
2021-10-05 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
CA3072634A1
(en)
|
2017-10-18 |
2019-04-25 |
Sabine Rauth |
Human serum albumin variants and uses thereof
|
CN111655725A
(zh)
|
2017-10-19 |
2020-09-11 |
德比奥药物国际股份有限公司 |
用于治疗癌症的组合产品
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
RU2020116579A
(ru)
|
2017-10-25 |
2021-11-25 |
Новартис Аг |
Способы получения клеток, экспрессирующих химерный антигенный рецептор
|
SG11202003980PA
(en)
|
2017-10-31 |
2020-05-28 |
Staten Biotechnology B V |
Anti-apoc3 antibodies and methods of use thereof
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
EP3704160A1
(de)
|
2017-10-31 |
2020-09-09 |
VIB vzw |
Neuartige antigenbindende chimäre proteine und verfahren und verwendungen davon
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
WO2019090148A2
(en)
|
2017-11-03 |
2019-05-09 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
US20210179721A1
(en)
|
2017-11-29 |
2021-06-17 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
JP2021505208A
(ja)
|
2017-12-05 |
2021-02-18 |
セリアド エス.アー.Celyad S.A. |
養子細胞療法用細胞の持続性を向上するための組成物および方法
|
US11639496B2
(en)
|
2017-12-05 |
2023-05-02 |
Celyad S.A. |
Reducing fratricide of immune cells expressing NKG2D-based receptors
|
EP3720881A1
(de)
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle und verwendungen davon
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CN115925943A
(zh)
|
2017-12-27 |
2023-04-07 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
US11905327B2
(en)
|
2017-12-28 |
2024-02-20 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
CN108218990B
(zh)
|
2017-12-29 |
2021-03-02 |
南京优迈生物科技有限公司 |
分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
|
WO2019140116A2
(en)
|
2018-01-10 |
2019-07-18 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
US10899823B2
(en)
|
2018-01-18 |
2021-01-26 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
US11965191B2
(en)
|
2018-01-18 |
2024-04-23 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
AU2019211326A1
(en)
|
2018-01-23 |
2020-09-10 |
Nextcure, Inc. |
B7-H4 antibodies and methods of use thereof
|
JP2021510594A
(ja)
|
2018-01-25 |
2021-04-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
臓器の虚血再灌流傷害を予防する方法における使用のためのil−33のアンタゴニスト
|
AU2019215031A1
(en)
|
2018-01-31 |
2020-08-20 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
EP3749690A1
(de)
|
2018-02-05 |
2020-12-16 |
Stichting VU |
Inverse agonistische anti-us28-antikörper
|
EP3749295A4
(de)
|
2018-02-05 |
2022-04-27 |
Orionis Biosciences, Inc. |
Fibroblastenbindende wirkstoffe und verwendung davon
|
MX2020008294A
(es)
|
2018-02-06 |
2020-11-18 |
Ablynx Nv |
Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
|
WO2019157191A1
(en)
|
2018-02-07 |
2019-08-15 |
Georgia Tech Research Corporation |
Methods for multiplexed cell isolation using dna gates
|
WO2019156566A1
(en)
|
2018-02-12 |
2019-08-15 |
Umc Utrecht Holding B.V. |
Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
|
WO2019155041A1
(en)
|
2018-02-12 |
2019-08-15 |
Vib Vzw |
Gβγ COMPLEX ANTIBODIES AND USES THEREOF
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
CA3092421A1
(en)
|
2018-03-01 |
2019-09-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
EP3765495A1
(de)
|
2018-03-13 |
2021-01-20 |
Smivet B.V. |
An tetanus-neurotoxin bindende einzeldomänenantikörper
|
CA3092635A1
(en)
|
2018-03-14 |
2019-09-19 |
Surface Oncology, Inc. |
Antibodies that bind cd39 and uses thereof
|
US20210238280A1
(en)
|
2018-03-14 |
2021-08-05 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP3765516A2
(de)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunktionale moleküle und verwendungen davon
|
EP3768720A4
(de)
|
2018-03-20 |
2022-01-05 |
Wuxi Biologics Ireland Limited |
Neuartiges anti-lag-3-antikörper-polypeptid
|
BR112020018918A2
(pt)
|
2018-03-22 |
2021-01-05 |
Surface Oncology, Inc. |
Anticorpos anti-il-27 e usos dos mesmos
|
AU2019237215B2
(en)
|
2018-03-23 |
2023-11-02 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules
|
EP3773665A1
(de)
|
2018-03-27 |
2021-02-17 |
UMC Utrecht Holding B.V. |
Gezielte thrombolyse zur behandlung von mikrovaskulärer thrombose
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
EP3775206A1
(de)
|
2018-03-28 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von krebs
|
CA3093034A1
(en)
|
2018-03-30 |
2019-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US20210164984A1
(en)
|
2018-04-13 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019217913A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
EP3794038A4
(de)
|
2018-05-14 |
2022-02-16 |
Harpoon Therapeutics, Inc. |
Bindungseinheit zur bedingten aktivierung von immunoglobulinmolekülen
|
EP3569618A1
(de)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisierender cd73-antikörper
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
WO2019226050A2
(en)
|
2018-05-24 |
2019-11-28 |
Wageningen Universiteit |
Novel viral anti-infective reagents
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
JP2021527409A
(ja)
|
2018-06-14 |
2021-10-14 |
ブルーバード バイオ, インコーポレイテッド |
Cd79aキメラ抗原受容体
|
WO2019246293A2
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
EP3816186A4
(de)
|
2018-06-29 |
2022-04-06 |
Suzhou Smartnuclide Biopharmaceutical Co., Ltd. |
Pd-l1-bindende polypeptide und verwendung davon
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
DE202019005887U1
(de)
|
2018-07-03 |
2023-06-14 |
Marengo Therapeutics, Inc. |
Anti-TCR-Antikörpermoleküle und Verwendungen davon
|
CA3106143A1
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
AU2019301126A1
(en)
|
2018-07-11 |
2021-02-04 |
Celgene Corporation |
Uses of anti-BCMA chimeric antigen receptors
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
US20210290633A1
(en)
|
2018-07-19 |
2021-09-23 |
INSERM (Insstitut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
EP3824287A1
(de)
|
2018-07-20 |
2021-05-26 |
Pierre Fabre Médicament |
Rezeptor für vista
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
ES2738926A1
(es)
|
2018-07-26 |
2020-01-27 |
Univ Zaragoza |
Granulisina, metodo de obtencion y usos
|
WO2020028909A1
(en)
|
2018-08-03 |
2020-02-06 |
Brown University |
Oral formulations with increased uptake
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
US11453893B2
(en)
|
2018-08-30 |
2022-09-27 |
California Institute Of Technology |
RNA-based delivery systems with levels of control
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
WO2020047320A1
(en)
|
2018-08-31 |
2020-03-05 |
California Institute Of Technology |
Synthetic protein circuits detecting signal transducer activity
|
BR112021003305A2
(pt)
|
2018-08-31 |
2021-05-25 |
Novartis Ag |
métodos para produzir células que expressam receptor de antígeno quimérico
|
JP7404343B2
(ja)
|
2018-09-04 |
2023-12-25 |
ナンジン ユーマブ-バイオファーマ カンパニー リミテッド |
融合タンパク質、並びに腫瘍及び/又はウイルス感染の治療薬を製造するためのその使用
|
GB201814451D0
(en)
|
2018-09-05 |
2018-10-17 |
Valerie Nicholas Carl Kristoffer |
Methods
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
WO2020053239A1
(en)
|
2018-09-11 |
2020-03-19 |
Nanotag Biotechnologies Gmbh |
Epitope tags recognized by specific binders
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
Dll3結合タンパク質および使用方法
|
WO2020064702A1
(en)
|
2018-09-25 |
2020-04-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
US20220242957A1
(en)
|
2018-09-27 |
2022-08-04 |
Marengo Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
US20210355216A1
(en)
|
2018-10-05 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
EP3870600A1
(de)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er-abstimmbare proteinregulierung
|
EP3873455A1
(de)
|
2018-10-31 |
2021-09-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur behandlung von t-helfer-typ-2-vermittelten krankheiten
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
CN113166269A
(zh)
|
2018-11-13 |
2021-07-23 |
指南针制药有限责任公司 |
对抗检查点分子的多特异性结合构建体及其用途
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
WO2020120644A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New anti tau svqivykpv epitope single domain antibody
|
EP3898686A1
(de)
|
2018-12-20 |
2021-10-27 |
Novartis AG |
Pharmazeutische kombinationen
|
WO2020130838A2
(en)
|
2018-12-21 |
2020-06-25 |
Qvq Holding B.V. |
Antibodies for preventing or treating candidiasis
|
JP2022515223A
(ja)
|
2018-12-21 |
2022-02-17 |
オーエスイー・イミュノセラピューティクス |
ヒトpd-1に対する二機能性分子
|
BR112021012040A2
(pt)
|
2018-12-21 |
2021-11-03 |
Ose Immunotherapeutics |
Molécula anti-pd-1/sirpa bifuncional
|
KR20210108978A
(ko)
|
2018-12-21 |
2021-09-03 |
오제 이뮈노테라프틱스 |
이작용성 항-pd-1/il-7 분자
|
BR112021013157A8
(pt)
|
2019-01-03 |
2022-12-06 |
Inst Nat Sante Rech Med |
Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células t
|
EP3908653A4
(de)
|
2019-01-10 |
2022-11-02 |
California Institute of Technology |
Synthetisches system zur abstimmbaren schwellenwertbildung von proteinsignalen
|
SG11202107606VA
(en)
|
2019-01-15 |
2021-08-30 |
Inst Nat Sante Rech Med |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
US20220119516A1
(en)
|
2019-01-16 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Variants of erythroferrone and their use
|
CA3127072A1
(en)
|
2019-01-16 |
2020-07-23 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
TWI756621B
(zh)
|
2019-01-25 |
2022-03-01 |
大陸商信達生物製藥(蘇州)有限公司 |
新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
AU2020223293A1
(en)
|
2019-02-15 |
2021-08-19 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
WO2020168024A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
CN114126714A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
CN114026122A
(zh)
|
2019-02-21 |
2022-02-08 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
CA3130628A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
EP3930757A1
(de)
|
2019-03-01 |
2022-01-05 |
President And Fellows Of Harvard College |
Verfahren und zusammensetzungen zur proteinabgabe
|
JP2022524081A
(ja)
|
2019-03-08 |
2022-04-27 |
オブシディアン セラピューティクス, インコーポレイテッド |
調整可能な制御のためのヒトカルボニックアンヒドラーゼ2組成物及び方法
|
EP3935084A1
(de)
|
2019-03-08 |
2022-01-12 |
LinXis B.V. |
Internalisierung von an die zellproliferation oder zelldifferenzierung beteiligten rezeptoren
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
JP2022524215A
(ja)
|
2019-03-28 |
2022-04-28 |
ダニスコ・ユーエス・インク |
改変抗体
|
MX2021011830A
(es)
|
2019-03-29 |
2022-01-24 |
Atarga Llc |
Anticuerpo anti fgf23.
|
JP2022527825A
(ja)
|
2019-04-03 |
2022-06-06 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20220276244A1
(en)
|
2019-04-29 |
2022-09-01 |
Confo Therapeutics N.V. |
Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
|
EP3962599A1
(de)
|
2019-04-30 |
2022-03-09 |
Vib Vzw |
Stabilisierungsmittel des transmembrankonduktanzregulators bei zystischer fibrose
|
SG11202110911RA
(en)
|
2019-05-13 |
2021-10-28 |
Regeneron Pharma |
Improved competitive ligand binding assays
|
US20220259561A1
(en)
|
2019-05-14 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
KR20220008866A
(ko)
|
2019-05-14 |
2022-01-21 |
하푼 테라퓨틱스, 인크. |
EpCAM 결합 단백질 및 사용 방법
|
EP3969472A1
(de)
|
2019-05-16 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von typ-2-entzündung oder von mastzellenabhängiger krankheit
|
EP3972634A2
(de)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Trispezifische bindungsmoleküle gegen bcma und verwendungen davon
|
WO2020236792A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
CN114206935B
(zh)
|
2019-05-24 |
2024-01-12 |
三优生物医药(上海)有限公司 |
新型cldn18.2结合分子
|
WO2020239945A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cancer treatment by targeting plexins in the immune compartment
|
WO2020239934A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
GB2584441A
(en)
|
2019-06-03 |
2020-12-09 |
Fenomark Diagnostics Ab |
Medical uses, methods and uses
|
WO2020244528A1
(zh)
|
2019-06-04 |
2020-12-10 |
上海吉倍生物技术有限公司 |
一种抗ceacam5的单克隆抗体及其制备方法和用途
|
CA3141561A1
(en)
|
2019-06-12 |
2020-12-17 |
Novartis Ag |
Natriuretic peptide receptor 1 antibodies and methods of use
|
WO2020257289A2
(en)
|
2019-06-17 |
2020-12-24 |
Visterra, Inc. |
Humanized antibody molecules to cd138 and uses thereof
|
JP2022537031A
(ja)
|
2019-06-20 |
2022-08-23 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
プロテアーゼネキシン-1に対する立体構造的な単一ドメイン抗体及びその使用
|
CA3144200A1
(en)
|
2019-06-21 |
2020-12-24 |
Sorriso Pharmaceuticals, Inc. |
Compositions
|
CN114466864A
(zh)
|
2019-06-21 |
2022-05-10 |
索瑞索制药公司 |
多肽
|
MX2021015763A
(es)
|
2019-06-21 |
2022-04-18 |
Sorriso Pharmaceuticals Inc |
Polipeptidos.
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
CN114466863A
(zh)
|
2019-07-01 |
2022-05-10 |
苏州康宁杰瑞生物科技有限公司 |
百日咳毒素结合蛋白
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
AU2020312686A1
(en)
|
2019-07-15 |
2022-02-03 |
Intervet International B.V. |
Caninized antibodies against canine CTLA-4
|
EP4004025A1
(de)
|
2019-07-26 |
2022-06-01 |
Visterra, Inc. |
Interleukin-2-wirkstoffe und verwendungen davon
|
WO2021025556A1
(en)
|
2019-08-05 |
2021-02-11 |
Stichting Vu |
Identification and elimination of hcmv-infected cells
|
CR20220076A
(es)
|
2019-08-30 |
2022-06-24 |
Agenus Inc |
Anticuerpos anti-cd96 y sus métodos de uso
|
WO2021046159A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
WO2021044012A1
(en)
|
2019-09-05 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment and pronostic of acute myeloid leukemia
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
JP2022548484A
(ja)
|
2019-09-16 |
2022-11-21 |
サーフィス オンコロジー インコーポレイテッド |
抗cd39抗体の組成物及び方法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
TW202126295A
(zh)
|
2019-09-27 |
2021-07-16 |
大陸商江蘇挪貝肽醫藥科技有限公司 |
一種治療心境障礙的方法
|
US20220290151A1
(en)
|
2019-09-27 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
TW202128756A
(zh)
|
2019-10-02 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
EP3799881A1
(de)
|
2019-10-04 |
2021-04-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Einzeldomänenantikörper, die spezifisch globo binden serie glycane
|
EP4048703A1
(de)
|
2019-10-21 |
2022-08-31 |
Vib Vzw |
Nanoscheibenspezifische antigenbindende chimäre proteine
|
EP4048285A1
(de)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3-inhibitoren und verwendungen davon
|
TW202128166A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
組合療法
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
WO2021086948A1
(en)
|
2019-10-28 |
2021-05-06 |
Georgia Tech Research Corporation |
Mrna-encoded antibodies for contraception
|
WO2021086953A1
(en)
|
2019-10-28 |
2021-05-06 |
Georgia Tech Research Corporation |
Compositions and methods for prophylaxis of hiv
|
JP2022554351A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレイション |
抗bcmaキメラ抗原受容体の使用法
|
US20220386594A1
(en)
|
2019-11-11 |
2022-12-08 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Insect control nanobodies and uses thereof
|
IL292836A
(en)
|
2019-11-12 |
2022-07-01 |
Actym Therapeutics Inc |
Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products
|
AU2020388387A1
(en)
|
2019-11-22 |
2022-06-02 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
AU2020393912A1
(en)
|
2019-11-26 |
2022-06-09 |
Novartis Ag |
Chimeric antigen receptors binding BCMA and CD19 and uses thereof
|
WO2021105384A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the nls region of nupr1 protein to treat cancer
|
EP4065603A1
(de)
|
2019-11-27 |
2022-10-05 |
Vib Vzw |
Positive allosterische modulatoren des calciumempfindlichen rezeptors
|
WO2021105391A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination comprising nupr1 inhibitors to treat cancer
|
CA3159155A1
(en)
|
2019-12-05 |
2021-06-10 |
Ose Immunotherapeutics |
Anti-clec-1a antibodies and antigen-binding fragment thereof
|
AU2020396204A1
(en)
|
2019-12-06 |
2022-07-28 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
EP4069293A1
(de)
|
2019-12-06 |
2022-10-12 |
Ablynx N.V. |
Polypeptide mit variablen immunglobulin-einzeldomänen zur abzielung auf tnfa und ox40l
|
MX2022007035A
(es)
|
2019-12-09 |
2022-06-23 |
Ablynx Nv |
Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
TW202136287A
(zh)
|
2019-12-17 |
2021-10-01 |
法商Ose免疫治療公司 |
包含il-7變體之雙官能分子
|
WO2021123360A1
(en)
|
2019-12-20 |
2021-06-24 |
Vib Vzw |
Nanobody exchange chromatography
|
CA3165399A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
EP4077385A4
(de)
|
2019-12-20 |
2023-12-13 |
Hudson Institute of Medical Research |
Cxcl10-bindende proteine und verwendungen davon
|
EP4084821A4
(de)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics Inc |
An cd33 bindende multifunktionsmoleküle und ihre verwendungen
|
MX2022008341A
(es)
|
2020-01-06 |
2022-08-10 |
Vaccinex Inc |
Anticuerpos anti-ccr8 y usos de estos.
|
WO2021140205A1
(en)
|
2020-01-10 |
2021-07-15 |
Confo Therapeutics N.V. |
Methods for generating antibodies and antibody fragments and libraries comprising same
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
CN114929285A
(zh)
|
2020-01-17 |
2022-08-19 |
根特大学 |
用于输送黏膜疫苗的免疫球蛋白单域抗体
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
EP4106806A1
(de)
|
2020-02-21 |
2022-12-28 |
Harpoon Therapeutics, Inc. |
Flt3-bindende proteine und verfahren zur verwendung
|
CA3168729A1
(en)
|
2020-02-24 |
2021-09-02 |
Melinda MATA |
Methods for expanding t cells for the treatment of cancer and related malignancies
|
WO2021170540A1
(en)
|
2020-02-25 |
2021-09-02 |
Vib Vzw |
Leucine-rich repeat kinase 2 allosteric modulators
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
MX2022010604A
(es)
|
2020-02-27 |
2022-09-09 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
JP2023515211A
(ja)
|
2020-02-27 |
2023-04-12 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
CN115485295A
(zh)
|
2020-03-10 |
2022-12-16 |
麻省理工学院 |
NPM1c阳性癌症的免疫疗法的组合物和方法
|
US20230149460A1
(en)
|
2020-03-10 |
2023-05-18 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
KR20220154140A
(ko)
|
2020-03-13 |
2022-11-21 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Pvrig 결합 단백질 및 이의 의학적 용도
|
WO2021186363A1
(en)
|
2020-03-20 |
2021-09-23 |
Glaxosmithkline Intellectual Property Development Limited |
Method for detecting polysorbates
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
US20230136595A1
(en)
|
2020-03-30 |
2023-05-04 |
Ablynx Nv |
Method for the production and purification of multivalent immunoglobulin single variable domains
|
CN113461817A
(zh)
|
2020-03-31 |
2021-10-01 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
US20230110053A1
(en)
|
2020-03-31 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
WO2021203024A1
(en)
|
2020-04-03 |
2021-10-07 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
US20230416344A1
(en)
|
2020-04-16 |
2023-12-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treating a complement mediated disorder caused by viruses
|
EP4144758A1
(de)
|
2020-04-22 |
2023-03-08 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Gegen den humanen liganden 1 für programmierten zelltod (pd-l1) gerichteter einzelvariabler domänenantikörper und derivat davon
|
EP4139363A1
(de)
|
2020-04-24 |
2023-03-01 |
Marengo Therapeutics, Inc. |
An t-zellen-verwandte krebszellen bindende multifunktionelle moleküle und verwendungen davon
|
BR112022022369A2
(pt)
|
2020-05-04 |
2023-03-14 |
Immunorizon Ltd |
Construtos precursores de anticorpo triespecífico e métodos de uso destes
|
JP2023525053A
(ja)
|
2020-05-12 |
2023-06-14 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
皮膚t細胞リンパ腫及びtfh由来リンパ腫を処置する新しい方法
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
WO2021233962A1
(en)
|
2020-05-19 |
2021-11-25 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
EP3916088A1
(de)
|
2020-05-28 |
2021-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusionsproteine, die die sars-cov-2-3-clpro-katalytische domäne enthalten, und ihre verwendung zum screening von anti-sars-cov-2-mitteln
|
EP4157923A2
(de)
|
2020-05-29 |
2023-04-05 |
President And Fellows Of Harvard College |
Mit polyphenolfunktionalisierten biologisch aktiven nanokomplexen manipulierte lebende zellen
|
IL298111A
(en)
|
2020-06-02 |
2023-01-01 |
Arcus Biosciences Inc |
Antibodies to tigit
|
CN111647077B
(zh)
|
2020-06-02 |
2021-02-09 |
深圳市因诺赛生物科技有限公司 |
新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
|
IL298473A
(en)
|
2020-06-11 |
2023-01-01 |
Novartis Ag |
zbtb32 inhibitors and uses thereof
|
EP4168006A1
(de)
|
2020-06-18 |
2023-04-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neue strategie zur behandlung von bauchspeicheldrüsenkrebs
|
EP4172206A1
(de)
|
2020-06-24 |
2023-05-03 |
Visterra, Inc. |
Antikörpermoleküle gegen april und verwendungen davon
|
EP4153636A1
(de)
|
2020-06-29 |
2023-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Einzeldomänenantikörper gegen protein s und polypeptide damit
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
AU2021302199A1
(en)
|
2020-07-03 |
2023-02-23 |
Suzhou Alphamab Co., Ltd. |
Coagulation factor XI (FXI) binding protein
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
WO2022017370A1
(zh)
|
2020-07-21 |
2022-01-27 |
苏州智核生物医药科技有限公司 |
Cd8结合多肽及其用途
|
JP2023535024A
(ja)
|
2020-07-23 |
2023-08-15 |
オター プロシーナ リミテッド |
抗aベータ抗体
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
EP4189060A1
(de)
|
2020-07-31 |
2023-06-07 |
Biotalys NV |
Expressionswirt
|
EP4196139A2
(de)
|
2020-08-12 |
2023-06-21 |
Actym Therapeutics, Inc. |
Impfstoffe auf der basis von immunstimulierenden bakterien, therapeutika und rna-freisetzungsplattformen
|
TW202227616A
(zh)
|
2020-08-21 |
2022-07-16 |
美商英麥提克斯股份有限公司 |
分離cd8+選擇t細胞的方法
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP4204458A1
(de)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
Verfahren zum nachweis von trbc1 oder trbc2
|
KR20230074144A
(ko)
|
2020-08-26 |
2023-05-26 |
마렝고 테라퓨틱스, 인크. |
NKp30에 결합하는 항체 분자 및 이의 용도
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023541455A
(ja)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
Cd33に対する単一ドメイン抗体
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
EP4214235A1
(de)
|
2020-09-16 |
2023-07-26 |
LinXis B.V. |
Internalisierung von bindungsmolekülen
|
WO2022063947A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
MX2023003522A
(es)
|
2020-09-25 |
2023-04-19 |
Ablynx Nv |
Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
|
WO2022084399A1
(en)
|
2020-10-21 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
US20220119535A1
(en)
|
2020-10-21 |
2022-04-21 |
Boehringer Ingelheim International Gmbh |
Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
|
US20230398149A1
(en)
|
2020-11-04 |
2023-12-14 |
Celgene Corporation |
Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
EP4255929A2
(de)
|
2020-12-02 |
2023-10-11 |
Vib Vzw |
Ltbr-agonist in kombinationstherapie gegen krebs
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
EP4256067A2
(de)
|
2020-12-04 |
2023-10-11 |
Tidal Therapeutics, Inc. |
Ionisierbare kationische lipide und lipidnanopartikel sowie verfahren zur synthese und verwendung davon
|
EP4255466A1
(de)
|
2020-12-04 |
2023-10-11 |
Visterra, Inc. |
Verfahren zur verwendung von interleukin-2-wirkstoffen
|
US20240016936A1
(en)
|
2020-12-04 |
2024-01-18 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
US20240052042A1
(en)
|
2020-12-14 |
2024-02-15 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
|
KR20230129441A
(ko)
|
2020-12-17 |
2023-09-08 |
오제 이뮈노테라프틱스 |
이기능성 항-pd1/il-7 분자
|
KR20230122084A
(ko)
|
2020-12-18 |
2023-08-22 |
아블린쓰 엔.브이. |
Tcr 알파/베타 반응성에 기초한 t 세포 동원 폴리펩타이드
|
KR20230123497A
(ko)
|
2020-12-18 |
2023-08-23 |
아블린쓰 엔.브이. |
IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
|
TW202241947A
(zh)
|
2020-12-18 |
2022-11-01 |
比利時商艾伯霖克斯公司 |
包含靶向磷脂醯肌醇蛋白聚糖—3和t細胞受體的免疫球蛋白單可變結構域的多肽
|
GB202020502D0
(en)
|
2020-12-23 |
2021-02-03 |
Vib Vzw |
Antibody composistion for treatment of corona virus infection
|
EP4267618A1
(de)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Nichtblockierende, menschliche ccr8-bindemittel
|
WO2022136650A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Murine cross-reactive human ccr8 binders
|
WO2022136647A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Human ccr8 binders
|
US20220226442A1
(en)
|
2021-01-20 |
2022-07-21 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
EP4284510A1
(de)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
CA3207206A1
(en)
|
2021-02-01 |
2022-08-04 |
Lingfeng LIU |
Targeted protein degradation system and use thereof
|
KR20230166078A
(ko)
|
2021-02-05 |
2023-12-06 |
샐러브리스 바이오테라퓨틱스, 인크. |
Il-15 융합 단백질 및 이를 제조 및 사용하는 방법
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
AU2022216460A1
(en)
|
2021-02-05 |
2023-09-21 |
Universiteit Gent |
Sarbecovirus binders
|
EP4291898A1
(de)
|
2021-02-12 |
2023-12-20 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur prognose und behandlung eines an krebs leidenden patienten
|
CN117241804A
(zh)
|
2021-02-17 |
2023-12-15 |
非营利性组织佛兰芒综合大学生物技术研究所 |
在癌症治疗中slc4a4的抑制
|
EP4294516A1
(de)
|
2021-02-19 |
2023-12-27 |
Vib Vzw |
Kationunabhängige mannose-6-phosphatrezeptorbindemittel
|
AU2022222423A1
(en)
|
2021-02-19 |
2023-09-28 |
Seoul National University R&Db Foundation |
Single domain antibody against pd-l1 and use thereof
|
JP2024509766A
(ja)
|
2021-02-19 |
2024-03-05 |
シャペロン インク. |
Pd-l1及びcd47に対する二重特異性単一ドメイン抗体及びその用途
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
WO2022177392A1
(ko)
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Cd47에 대한 단일 도메인 항체 및 이의 용도
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
GB202104104D0
(en)
|
2021-03-24 |
2021-05-05 |
Liliumx Ltd |
Platform and method
|
WO2022199804A1
(en)
|
2021-03-24 |
2022-09-29 |
Vib Vzw |
Nek6 inhibition to treat als and ftd
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
US20220333074A1
(en)
|
2021-04-07 |
2022-10-20 |
Century Therapeutics, Inc. |
Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
|
JP2024513454A
(ja)
|
2021-04-07 |
2024-03-25 |
センチュリー セラピューティクス,インコーポレイテッド |
キメラ抗原受容体細胞のための人工細胞死/リポーター系ポリペプチドの組合せおよびその使用
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20230170703A
(ko)
|
2021-04-07 |
2023-12-19 |
센츄리 쎄라퓨틱스 인코포레이티드 |
유도 만능 줄기세포로부터 감마-델타 t 세포의 생성을 위한 조성물 및 방법
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
WO2022214653A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
WO2022216157A1
(en)
|
2021-04-09 |
2022-10-13 |
Stichting Radboud Universiteit |
Off the shelf proximity biotinylation enzyme
|
EP4320156A1
(de)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Gerüst für bifunctioanlmoleküle mit pd-1- oder cd28- und sirp-bindenden domänen
|
EP4322938A1
(de)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neues verfahren zur verbesserung der zytotoxizität von nk-zellen
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
CN117529333A
(zh)
|
2021-04-16 |
2024-02-06 |
细胞基因公司 |
对先前进行过干细胞移植的患者的t细胞疗法
|
WO2022235628A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
JP2024516970A
(ja)
|
2021-05-07 |
2024-04-18 |
サーフィス オンコロジー, エルエルシー |
抗il-27抗体及びその使用
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
EP4357365A1
(de)
|
2021-06-16 |
2024-04-24 |
Shanghai Sinobay Biotechnology Co., Ltd. |
Antikörper gegen axl-protein und antigenbindendes fragment davon sowie herstellungsverfahren dafür und anwendung davon
|
TW202317625A
(zh)
|
2021-06-17 |
2023-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
新穎三特異性結合分子
|
CN117545776A
(zh)
|
2021-06-22 |
2024-02-09 |
默克专利股份公司 |
基于vhh的nkp30粘结剂
|
EP4359421A1
(de)
|
2021-06-23 |
2024-05-01 |
Vib Vzw |
Mittel und verfahren zur auswahl spezifischer bindemittel
|
WO2022269473A1
(en)
|
2021-06-23 |
2022-12-29 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
CN114230665B
(zh)
|
2021-06-23 |
2024-03-22 |
苏州智核生物医药科技有限公司 |
CD8α结合多肽及其用途
|
WO2023274183A1
(zh)
|
2021-06-29 |
2023-01-05 |
江苏先声药业有限公司 |
Cd16抗体及其应用
|
WO2023288046A1
(en)
|
2021-07-15 |
2023-01-19 |
President And Fellows Of Harvard College |
Compositions and methods relating to cells with adhered particles
|
CA3228014A1
(en)
|
2021-07-30 |
2023-02-16 |
Vib Vzm |
Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
|
WO2023006040A1
(zh)
|
2021-07-30 |
2023-02-02 |
江苏先声药业有限公司 |
抗pvrig/抗tigit双特异性抗体和应用
|
WO2023012343A1
(en)
|
2021-08-06 |
2023-02-09 |
Institut Du Cancer De Montpellier |
Methods for the treatment of cancer
|
WO2023023227A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
CN117616049A
(zh)
|
2021-08-24 |
2024-02-27 |
江苏恒瑞医药股份有限公司 |
Fap/cd40结合分子及其医药用途
|
WO2023041985A2
(en)
|
2021-09-15 |
2023-03-23 |
New York University In Abu Dhabicorporation |
Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
|
CA3231553A1
(en)
|
2021-09-15 |
2023-03-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
|
TW202328195A
(zh)
|
2021-09-15 |
2023-07-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合pd-1的蛋白及其醫藥用途
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
WO2023057484A1
(en)
|
2021-10-06 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
CA3233824A1
(en)
|
2021-10-08 |
2023-04-13 |
Samir Mitragotri |
Ionic liquids for drug delivery
|
WO2023073099A1
(en)
|
2021-10-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to improve phagocytosis
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
WO2023079137A1
(en)
|
2021-11-05 |
2023-05-11 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
CA3235418A1
(en)
|
2021-11-09 |
2023-05-19 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
|
WO2023083890A1
(en)
|
2021-11-09 |
2023-05-19 |
Ose Immunotherapeutics |
Identification of clec-1 ligand and uses thereof
|
EP4180518A1
(de)
|
2021-11-12 |
2023-05-17 |
Istituto Europeo di Oncologia S.r.l. |
T-zellen und deren verwendungen
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
WO2023089191A1
(en)
|
2021-11-22 |
2023-05-25 |
Ablynx N.V. |
Obtaining sequence information for target multivalent immunoglobulin single variable domains
|
WO2023097254A1
(en)
|
2021-11-24 |
2023-06-01 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023095034A1
(en)
|
2021-11-24 |
2023-06-01 |
Novartis Ag |
Modulators of adeno-associated virus transduction and uses thereof
|
WO2023102463A1
(en)
|
2021-12-01 |
2023-06-08 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
TW202334405A
(zh)
|
2021-12-15 |
2023-09-01 |
美商英特瑞斯生物療法公司 |
假型分型之病毒顆粒、包含其之組合物及其用途
|
TW202342508A
(zh)
|
2021-12-17 |
2023-11-01 |
比利時商艾伯霖克斯公司 |
包含靶向TCRαβ、CD33和CD123的免疫球蛋白單可變結構域的多肽
|
EP4209508A1
(de)
|
2022-01-11 |
2023-07-12 |
Centre national de la recherche scientifique |
Nanokörpern für das deneddylierende enzym nedp1
|
WO2023135198A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
Human ntcp binders for therapeutic use and liver-specific targeted delivery
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023148291A1
(en)
|
2022-02-02 |
2023-08-10 |
Biotalys NV |
Methods for genome editing
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
WO2023148397A1
(en)
|
2022-02-07 |
2023-08-10 |
Vib Vzw |
Engineered stabilizing aglycosylated fc-regions
|
WO2023151894A1
(en)
|
2022-02-11 |
2023-08-17 |
Henkel Ag & Co. Kgaa |
Process for the synthesis of alpha-methylene-gamma-butyrolactone
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
WO2023183474A1
(en)
|
2022-03-23 |
2023-09-28 |
Bodhi Bio Llc |
Antigen-specific therapy for autoimmune diseases
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023198848A1
(en)
|
2022-04-13 |
2023-10-19 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
WO2023198806A1
(en)
|
2022-04-13 |
2023-10-19 |
Ose Immunotherapeutics |
New class of molecules for selective clearance of antibody
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
US20240092921A1
(en)
|
2022-04-25 |
2024-03-21 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
WO2023212587A1
(en)
|
2022-04-28 |
2023-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023213751A1
(en)
|
2022-05-02 |
2023-11-09 |
Umc Utrecht Holding B.V |
Single domain antibodies for the detection of plasmin-cleaved vwf
|
WO2023217904A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023222825A1
(en)
|
2022-05-18 |
2023-11-23 |
Vib Vzw |
Sarbecovirus spike s2 subunit binders
|
US20230372395A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023232826A1
(en)
|
2022-05-30 |
2023-12-07 |
Ose Immunotherapeutics |
Biomarkers of il7r modulator activity
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
US20240109965A1
(en)
|
2022-06-14 |
2024-04-04 |
Ablynx N.V. |
Immunoglobulin single variable domains targeting t cell receptor
|
WO2024003873A1
(en)
|
2022-06-30 |
2024-01-04 |
Intrexon Actobiotics Nv D/B/A Precigen Actobio |
Single variable domain antibodies against tumor necrosis factor-alpha
|
EP4299124A1
(de)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2-nanokörper zur verwendung als biomolekültransporter
|
EP4299125A1
(de)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2-biparatopische nanokörper und deren verwendungen
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024008904A2
(en)
|
2022-07-08 |
2024-01-11 |
Novo Nordisk A/S |
Highly potent isvd compounds capable of substituting for fviii(a)
|
US20240052065A1
(en)
|
2022-07-15 |
2024-02-15 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
US20240117038A1
(en)
|
2022-07-18 |
2024-04-11 |
Ablynx N.V. |
Cx3cr1-binding compounds, methods and uses thereof
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024023271A1
(en)
|
2022-07-27 |
2024-02-01 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
WO2024028347A1
(en)
|
2022-08-01 |
2024-02-08 |
Ose Immunotherapeutics |
Heterodimeric fc-clec-1 fusion molecule and uses thereof
|
WO2024028386A1
(en)
|
2022-08-02 |
2024-02-08 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024049951A1
(en)
|
2022-08-31 |
2024-03-07 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of fusion polypeptides for treatment of sickle cell disease
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024055034A1
(en)
|
2022-09-09 |
2024-03-14 |
Yale University |
Proteolysis targeting antibodies and methods of use thereof
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024068744A1
(en)
|
2022-09-27 |
2024-04-04 |
Vib Vzw |
Antivirals against human parainfluenza virus
|
WO2024069180A2
(en)
|
2022-09-28 |
2024-04-04 |
LiliumX Ltd. |
Multivalent proteins and screening methods
|
WO2024068944A1
(en)
|
2022-09-30 |
2024-04-04 |
Sanofi |
Anti-cd28 antibodies
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|